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Abstract: The occurrence of invasive fungal infections represents a substantial threat to human health
that is particularly serious in immunocompromised patients. The limited number of antifungal
agents, devoid of unwanted toxic effects, has resulted in an increased demand for new drugs. Herein,
the chalcone framework was functionalized to develop new antifungal agents able to interfere with
cell growth and with the infection process. Thus, a small library of chalcone-based analogues was
evaluated in vitro against C. albicans ATCC 10231 and a number of compounds strongly inhibited
yeast growth at non-cytotoxic concentrations. Among these, 5 and 7 interfered with the expression
of two key virulence factors in C. albicans pathogenesis, namely, hyphae and biofilm formation,
while 28 emerged as a potent and broad spectrum antifungal agent, enabling the inhibition of the
tested Candida spp. and non-Candida species. Indeed, these compounds combine two modes of
action by selectively interfering with growth and, as an added value, weakening microbial virulence.
Overall, these compounds could be regarded as promising antifungal candidates worthy of deeper
investigation. They also provide a chemical platform through which to perform an optimization
process, addressed at improving potency and correcting liabilities.
Keywords: anti-virulence agents; biofilm; Candida albicans chalcone scaffold; clinically relevant yeasts;
fluorine atom; yeast-to-hyphae transition
1. Introduction
Life-threatening invasive fungal infections (IFIs) have been widely recognized as the “hidden
killers” of immunocompromised individuals such as patients subjected to organ transplantation and
those affected by cancer or AIDS [1,2]. Recently, IFIs have become a severe health problem due to their
association with high incidence and mortality [3]. Candidiasis is the main etiologic factor triggering
IFIs, with a mortality rate ranging from 46% to 75% for Candida albicans, and from 20% to 70% for
Cryptococcus neoformans [2].
Candida spp. are members of the commensal human microflora in anatomically distinct sites
(oral, gastrointestinal, and genitourinary tracts) but, as stated above, under an extensive variety of
circumstances (specific immune defects, mucosal or cutaneous barrier disruption, ageing, diabetes,
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AIDS) they can be responsible for a wide spectrum of serious clinical symptoms. The pathogenicity of
the Candida spp. is attributed to critical virulence factors, such as yeast-hyphal transition, adherence
to surfaces, production of proteolytic enzymes, and the formation of biofilm, a structure consisting
of multicellular microbial communities embedded in a self-produced polymeric matrix [4]. One of
the main consequences of the biofilm mode of growth is the enhanced resistance to host defense
mechanisms and antifungal drugs, which is why biofilm-associated infections are frequently refractory
to conventional therapy. Even if the incidence of resistance among human fungal pathogens is low
to moderate compared to antibiotic resistance among bacterial pathogens, the rising problem of
multi-drug resistance is becoming a major concern for clinicians. Moreover, epidemiological data
reveal that, although C. albicans remains the most common species isolated in superficial and invasive
fungal infections, the distribution is changing and other yeasts, including opportunistic and ubiquitous
saprophytic fungus, are increasingly recovered in immunocompromised hosts, particularly those with
central venous catheters or other indwelling devices [5,6].
At present, only a limited number of antifungal agents, namely fluconazole (FLC, Figure 1),
voriconazole, and itraconazole, most of which are characterized by an azole function, are in
preclinical or clinical studies or available for IFIs treatment [7]. Several limitations such as restricted
spectrum of action, toxicity, low efficacy, emergence of resistance, and critical pharmacodynamic and
pharmacokinetic profiles, have been recognized to plague this class of therapeutics [8]. On the other
hand, Amphotericin B, a very effective and broad-spectrum therapeutic agent for fungal infections, has
also shown several side effects [9]. In this scenario, the discovery of novel compounds active against
human pathogenic yeasts is an urgent need. Ideally, an antifungal agent should be broad-spectrum,
effective against both morphotypes of the yeast (blastospore and hyphae) and biofilms, but also
able to reduce the expression of virulence factors. Valuable in this respect are natural products
(NPs) and plant-derived secondary metabolites, which exert antimicrobial activity without conferring
resistance [10]. NPs, small molecules synthesized by the plant kingdom, define evolutionarily chosen
“privileged structures” [11] since they have evolved in a natural selection process to achieve optimal
interactions with biological macromolecules. Thus, NPs-inspired compound collections may allow the
identification of new molecular templates, suitable for the design of new effective antimicrobial agents.
The pharmaceutical industry has extensively relied on NP classes for the discovery of antimicrobics,
including polyenes and echinocandins [12]
In this respect, chalcones (1,3-diaryl-2-propen-1-ones) are a prominent class of secondary
metabolites and precursors of flavonoids endowed with a wide range of activities, including
anti-oxidant, anti-metastatic, anti-inflammatory, and antimicrobial, as extensively reported in many
reviews [13]. The molecular basis of chalcones pleiotropic behavior, involving the modulation of
multiple biochemical pathways, are likely to be ascribed to their sulfhydryl reactive α,β-unsaturated
carbonyl function, a motif largely found in a variety of bioactive NPs. Indeed, the chalcone scaffold
demonstrated its suitability to serve as a chemical platform to obtain, upon properly addressed
modifications, small compound libraries that may allow performing structure-activity relationship
(SAR) studies [14,15].
Licochalcone A (Figure 1 and Table 1), isolated from the roots of the Chinese plant Glycyrrhiza glabra,
has been shown to inhibit the in vitro growth of different strains of C. albicans, both sensitive and
resistant to FLC, with minimum inhibitory concentration (MIC) values in the 62.5–150 µM range.
Moreover, at 650 µM concentration, it reduces yeast viability within a mature biofilm [16].
2. Results
2.1. Design Strategy
In an effort to uncover new starting points for antifungal drug discovery, an in-house small
library of chalcone-based analogues (Table 1) was screened against C. albicans, as a continuation of
our exploration of this privileged scaffold as suitable template for developing anti-infective agents.
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Indeed, some members of the library have been previously tested versus Leishmania donovani [17],
and a number of compounds endowed with encouraging in vitro activity were identified. To gain
insight into the key features for eliciting the antifungal effect, the chemical variability of the chalcones
regarded the substitution patterns of the A- and B-rings, as depicted in Figure 1, resulting in Series I, II,
and III. Concerning the A-ring: a) Series I was characterized by a 2,5-substutution pattern; in particular,
a hydroxyl group was introduced into the 2-position, while a halogen atom such as chlorine or fluorine
occupies the 5-position to give Series Ia and Ib, respectively. b) Series II was characterized by a
2,4-disubstitution pattern; in details, position-2 was decorated with hydroxy, methoxy, or propargyloxy
functions, while various alkoxy functions were appended into the 4-position. c) Series III contained an
alkoxy function into the 4-position. Regarding the B-ring, the following substituents were frequently
introduced: 2,4-diCl, 4-dimethylamino, 4-nitro, 4-fluorine, 3- and 4-pyridyl. A number of tested
compounds were characterized by a pyridine heterocyclic nucleus (12, 13, 16, 20, 21, 24, 25, 32, 33,
36, 37) as a privileged moiety present in several anti-infective agents [18], and by a F-phenyl ring (2–5,
7, 8, 10, 18, 22, 28-31). This small and highly electronegative atom confers special chemical reactivity
to the molecule by imparting several favorable properties including improved metabolic stability,
selectivity, and efficacy in binding [19]. Taking advantage of these important issues, we successfully
exploited this substituent for drug discovery purposes [20,21].
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was then reacted with phenylpiperazine to achieve intermediate 48. Acetophenone 49 was obtained 
through a Huisgen cycloaddition (click chemistry) reaction between the alkyne 45 and 2-azidoethan-
1-ol in the presence of CuSO4 and Na‒ascorbate as catalysts. An aldol condensation (Claisen‒
Schmidt) procedure allowed obtaining the chalcone-based analogues. In detail, three different 
reaction conditions were employed: 50% aqueous NaOH solution; piperidine/acetic acid; Ba(OH)2 
reported as Routes A, B, and C, respectively.  
  
Figure 1. Structure of fluconazole, licochalcone A, and general structures of the tested chalcones.
2.2. Chemistry
The final compounds were obtained as described in Scheme 1. The Williamson etherification
of 2,4-dihydroxyacetophenone with the appropriate alkyl bromide in the presence of K2CO3
allowed obtaining the acetophenone-based intermediates (41–45, 46, 47). In particular, treatment
of 2,4-dihydroxyacetophenone with 3,3-dimethylallylbromide, propargylbromide or 1-Br,2-Cl-ethane
allowed obtaining 41, 42 [17] and 43, respectively [21] that were subsequently alkylated with
methyliodide to give 44, 45 [17], and 46. Alkylation of 42 with propargylbromide gave 47 [17],
which was then reacted with phenylpiperazine to achieve intermediate 48. Acetophenone 49 was
obtained through a Huisgen cycloaddition (click chemistry) reaction between the alkyne 45 and
2-azidoethan-1-ol in the presence of CuSO4 and Na-ascorbate as catalysts. An aldol condensation
(Claisen-Schmidt) procedure allowed obtaining the chalcone-based analogues. In detail, three different
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reaction conditions were employed: 50% aqueous NaOH solution; piperidine/acetic acid; Ba(OH)2
reported as Routes A, B, and C, respectively.Molecules 2018, 23, x FOR PEER REVIEW  4 of 27 
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2.3. Biological Evaluation
A screening pipeline was developed to assess the therapeutic potential of the synthesized
molecules (1–40). The antifungal activity was firstly investigated as ability to affect in vitro C. albicans
growth (control strain, ATCC 10231). A set of compounds were then selected for their ability to show
an inhibitory activity superior to 50% at 100 µ , and for these the IC50 were determined. Afterwards,
these derivatives were subjected to dose-effect safety experiments in mammalian epithelial cells
(Vero, ATCC CCL-81). Chalcones having a positive selectivity index (SI), calculated as CC5 /IC50
ratio, were further investigated to measure their effect on different stages of fungal virulence, namely
yeast-to-hyphae morphological transition, filaments invasion, and biofilm formation. Moreover, these
active compounds were also assayed on a panel of ten pathogenic yeasts obtained from clinical
speci ens, including Candida spp. and non-Candida species, in order to fully characterize their
antifungal potential.
2.3.1. Specific Inhibition of Candida albicans Growth
The tested analogues 1–40 were firstly evaluated against C. albicans ATCC 10231 at 100 µM.
The commercially available antifungal FLC was used as running control to check the quality of
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the tests (growth/inhibition of the strains as defined by EUCAST guidelines) [22]. For compounds
demonstrating activity against fungal growth superior to 50%, IC50 values were determined from
a six-point dose-response curve, obtained in the concentration range 200–6.25 µM. From the data
reported in Table 1 (expressed both in µM and in µg/mL) some general structure-activity relationships
(SAR) can be drawn. Positively, sixteen out of the tested forty small molecules successfully inhibited
C. albicans growth.
Series Ia provided a number of active derivatives. In detail, the simple phenyl ring (as in
compound 1), along with the 3-F-, 4-F-, and 3,5-di-F-phenyl substitution (compounds 3, 4, and 5,
respectively) resulted in potent inhibition of cell growth, with IC50 values ranging from 48.9 µM
to 57.7 µM. On the contrary, the 2-F-phenyl function negatively affected activity (compound 2,
35.8% of inhibition), while the 4-dimethylaminophenyl moiety (6) resulted in an inactive compound.
Replacement of the 5-Cl of the A-ring with a fluorine atom (Series Ib) seemed not to affect the activity
of derivative 7, which maintained a good antifungal effect (IC50 = 53 µM), comparable to that of 3.
Surprisingly, a loss of potency, with respect to 4, was observed for the 4-F substituted 8, while increased
activity was obtained with the 4-dimethylamino (9, 38.5% of inhibition).
The effect elicited by the pyridine-based B-ring in conferring antifungal activity was extensively
investigated. Among the sub-set with a 4-propargyloxy side chain (compounds 12, 13, 16, 24, and
25), promising results were observed (IC50 values ranging from 8.1 to 43.8 µM). In particular, 13,
characterized by the methoxy group in the 2-position and the 4-pyridyl function, proved to be one of
the most active within the series (IC50 = 8.1 µM). The 3-pyridyl analogue 12, structurally related to 13,
showed decreased inhibitory potency (IC50 = 30.7 µM), while compound 16, the demethylated analogue
of 12, was as active as 13 (IC50 value of 10.8 µM). In the same way, the 2,4-di-propargyloxylated 24
and 25 (4- and 3- pyridine, respectively), showed inhibitory values of 26.3 µM and 43.8 µM. Also,
analogues 20 and 21, characterized by the 2-hydroxy and 4-(3,3-dimethylalliloxy) moieties, turned
out to remarkably inhibit C. albicans, as potencies in the single-digit micromolar range were observed.
The pyridine-based chalcones 32, 33, 36, and 37, in which the 2-substituent was removed (Series III),
proved to be devoid of any effect.
All chalcones bearing the 4-dimethylaminophenyl (15, 17, 27, 35, 39) and the 2,4-di-Cl-phenyl (11,
19, 23) functions as B–ring were inactive (Series II). Regarding the 4-nitro substitution of the B-ring,
good inhibitory effects were observed (14 and 26, IC50 = 39.2 µM and 36.8 µM, respectively). Again,
the corresponding nitro-analogues of Series III (34 and 38) turned out to be inactive.
In addition, the effect elicited by the presence of the fluorine atom on the B-ring was investigated
through a number of compounds (10, 18, 22, 28–31) characterized by different substituents on the
A-ring. In this regard, chalcones with simple alkoxylated functions showed poor activity: compound
22 was inactive and analogues 10 and 18 inhibited the C. albicans growth with percentages of 23.3 and
34.1, respectively. Interestingly, the decoration of the A-ring with hydrophilic functions (compounds
28–31) showed different behavior. The ethoxyphenylpiperazine (28) conferred a good antifungal
effect: IC50 value of 55.9 µM. On the contrary, 30, characterized by a 2-hydroxyethyl-1H-1,2,3-triazole,
proved to be inactive. In addition, poor inhibition was noticed for 29 with a more hydrophilic
phenol group. Conversely, 31, with a 4-hydroxyethoxy side chain, displayed a very good inhibitory
effect (IC50 = 12.0 µM). Finally, the cyclization of the chalcone scaffold into the constrained
2-arylidenebenzofuran-3-one (aurone), still maintaining the unsaturated carbonyl framework, was
performed for 13, to obtain derivative 40. This last modification caused a loss in activity, leading us
to assume that an optimal inhibitory effect is governed by the presence of the propen-1-one flexible
linker between aryl A- and B-rings.
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Table 1. Antifungal effect of chalcone-based analogues 1–40 against C. albicans control strain.
Compound Structure Inhibition (%)[at 100 µM] IC50 [µM]
a,b IC50 [µg/mL] a,b
1
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3 
 
64.8 ± 1.5 
57.7  
[47.1–70.8] 
16.0  
[13.0–19.6] 
4 
 
65.6 ± 3.3 
48.9  
[41.9–57.0] 
13.5  
[11.6– 5.8] 
 
 
62.0 ± 1.5 
51.3  
[41.3–63.8] 
15.1  
[12.2–18.8] 
6 
 
<1 n.d. n.d. 
7 
 
69.0 ± 12.4 
53.0  
[43.8–64.0] 
13.8  
[11.4–16.7] 
8 
 
<1 n.d. n.d. 
9 
 
38.5 ± 2.9 n.d. n.d. 
10 c 
 
23.3 ± 9.6 n.d. n.d. 
11 
 
9.8 ± 6.7 n.d. n.d. 
12 c 
 
>99 
30.7  
[27.0–35.0] 
9.0  
[7.9–10.3]. 
13 c 
 
>99 
8.1  
[6.8–9.6] 
2.4  
[2.0–2.8] 
. 1.5 51.3 [41.3–63.8] 15.1 [12.2–18.8]
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2 
 
35.8 ± 1.1 n.d. n.d. 
3 
 
64.8 ± 1.5 
57.7  
[47.1–70.8] 
16.0  
[13.0–19.6] 
4 
 
65.6 ± 3.3 
48.9  
[41.9–57.0] 
13.5  
[11.6–15.8] 
5 
 
62.0 ± 1.5 
51.3  
[41.3–63.8] 
15.1  
[12.2–18.8] 
6 
 
<1 n.d. n.d. 
7 
 
69.0 ± 12.4 
53.0  
[43.8–64.0] 
13.8  
[11.4–16.7] 
8 
 
<1 n.d. n.d. 
9 
 
38.5 ± 2.9 n.d. n.d. 
10 c 
 
23.3 ± 9.6 n.d. n.d. 
11 
 
9.8 ± 6.7 n.d. n.d. 
12 c 
 
>99 
30.7  
[27.0–35.0] 
9.0  
[7.9–10.3]. 
13 c 
 
>99 
8.1  
[6.8–9.6] 
2.4  
[2.0–2.8] 
n.d. n.d.
7
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2 
 
35.8 ± 1.1 n.d. n.d. 
3 
 
64.8 ± 1.5 
57.7  
[47.1– 0.8] 
16.0  
[13.0–19.6] 
4 
 
65.6 ± 3.3 
48.9  
[41.9–57.0] 
13.5  
[11.6–15.8] 
5 
 
62.0 ± 1.5 
51.3  
[41.3–63.8] 
15.1  
[12.2– 8.8] 
6 
 
<1 n.d. n.d. 
 
 
69.0 ± 12.4 
53.0  
[43.8–64.0] 
13.8  
[11.4–16.7] 
8 
 
<1 n.d. n.d. 
9 
 
38.5 ± 2.9 n.d. n.d. 
10 c 
 
23.3 ± 9.6 n.d. n.d. 
11 
 
9.8 ± 6.7 n.d. n.d. 
12 c 
 
>99 
30.7  
[27.0–35.0] 
9.0  
[7.9–10.3]. 
13 c 
 
>99 
8.1  
[6. –9.6] 
2.4  
[2.0–2.8] 
12.4 53.0 [43.8–64.0] 13.8 [11.4–16.7]
8
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2 
 
35.8 ± 1.1 n.d. n.d.
3 
 
64.8 ± 1.5 
57.7  
[47.1– 0.8] 
16.0  
[13.0–19.6] 
4 
 
65.6 ± 3.3 
48.9  
[41.9–57.0] 
13.5  
[11.6–15.8] 
5 
 
62.0 ± 1.5 
51.3  
[41.3–63.8] 
15.1  
[12.2– 8.8] 
6 
 
<1 n.d. n.d. 
7 
 
69.0 ± 12.4 
53.0  
[43.8–64.0] 
13.8  
[11.4–16.7] 
 
 
<1 n.d. n.d. 
9 
 
38.5 ± 2.9 n.d. n.d. 
10 c 
 
23.3 ± 9.6 n.d. n.d. 
11 
 
9.8 ± 6.7 n.d. n.d. 
12 c 
 
>99 
30.7  
[27.0–35.0] 
9.0  
[7.9–10.3]. 
13 c 
 
>99 
8.1  
[6. –9.6] 
2.4  
[2.0–2.8] 
n.d. n.d.
9
Molecules 2018, 23, x FOR PEER REVIEW  6 of 27 
 
2 
 
35.8 ± 1.1 n.d. n.d. 
3 
 
64.8 ± 1.5 
57.7  
[47.1–70.8] 
16.0  
[13.0–19.6] 
4 
 
65.6 ± 3.3 
48.9  
[41.9–57.0] 
13.5  
[11.6–15.8] 
5 
 
62.0 ± 1.5 
51.3  
[41.3–63.8] 
15.1  
[12.2–18.8] 
6 
 
<1 n.d. n.d. 
7 
 
69.0 ± 12.4 
53.0  
[43.8–64.0] 
13.8  
[11.4–16.7] 
8 
 
<1 n.d. n.d. 
 
 
38.5 ± 2.9 n. . n. . 
10 c 
 
23.3 ± 9.6 n. . n. . 
11 
 
9.8 ± 6.7 n. . n. . 
12 c 
 
>99 
30.7  
[27.0–35.0] 
9.0  
[7.9–10.3]. 
13 c 
 
>99 
8.1  
[6.8–9.6] 
2.4  
[2.0–2.8] 
. 2.9 n.d. n.d.
10 c
Molecules 2018, 23, x FOR PEER REVIEW  6 of 27 
 
2 
 
35.8 ± 1.1 n.d. n.d. 
3 
 
64.8 ± 1.5 
57.7  
[47.1– 0.8] 
16.0  
[13.0–19.6] 
4 
 
65.6 ± 3.3 
48.9  
[41.9–57.0] 
13.5  
[11.6–15.8] 
5 62.0 ± 1.5 
51.3  
[41.3–63.8] 
15.1  
[12.2– 8.8] 
6 
 
<1 n.d. n.d.
7 
 
69.0 ± 12.4 
53.0  
[43.8–64.0] 
13.8  
[11.4–16.7] 
8 
 
<1 n.d. n.d.
9 
 
38.5 ± 2.9 n.d. n.d. 
  
 
23.3 ± 9.6 n.d. n.d. 
11 
 
9.8 ± 6.7 n.d. n.d. 
12 c 
 
>99 
30.7  
[27.0–35.0] 
9.0  
[7.9–10.3]. 
13 c 
 
>99 
8.1  
[6. –9.6] 
2.4  
[2.0–2.8] 
. 9.6 n.d. n.d.
11
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2 
 
35.8 ± 1.1 n.d. n.d. 
3 
 
64.8 ± 1.5 
57.7  
[47.1–70.8] 
16.0  
[13.0–19.6] 
4 
 
65.6 ± 3.3 
48.9  
[41.9–5 .0] 
13.5  
[11.6–15.8] 
5 
 
62.0 ± 1.5 
51.3  
[41.3–63.8] 
15.1  
[12.2–18.8] 
6 
 
<1 n.d. n.d. 
7 
 
69.0 ± 12.4 
53.0  
[43.8–64.0] 
13.8  
[11.4–16.7] 
8 
 
<1 n.d. n.d. 
9 
 
38.5 ± 2.9 n.d. n.d. 
10 c 
 
23.3 ± 9.6 n.d. n.d. 
1  
 
9.8 ± 6.7 n.d. n.d. 
12 c 
 
>99 
30.7  
[27.0–35.0] 
9.0  
[7.9–10.3]. 
13 c 
 
>99 
8.1  
[6.8–9.6]
2.4  
[2.0–2.8] 
9.8 ± 6.7 n.d. n.d.
12 c
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2 
 
35.8 ± 1.1 n.d. n.d. 
3 
 
64.8 ± 1.5 
57.7  
[47.1–70.8] 
16.0  
[13.0–19.6] 
4 
 
65.6 ± 3.3 
48.9  
[41.9–57.0] 
13.5  
[11.6–15.8] 
5 
 
62.0 ± 1.5 
51.3  
[41.3–63.8] 
15.1  
[12.2–18.8] 
6 
 
<1 n.d. n.d. 
7 
 
69.0 ± 12.4 
53.0  
[43.8–64.0] 
13.8  
[11.4–16.7] 
8 
 
<1 n.d. n.d. 
9 
 
38.5 ± 2.9 n.d. n.d. 
10 c 
 
23.3 ± 9.6 n.d. n.d. 
11 
 
9.8 ± 6.7 n.d. n.d. 
 c 
 
>99 
30.7  
[27.0–35.0] 
9.0  
[7.9–1 .3]. 
13 c 
 
>99 
8.1  
[6.8–9.6] 
2.4  
[2.0–2.8] 
99 [27.0–35.0] 9.0 [7.9–10.3].
13 c
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2 
 
35.8 ± 1.1 n.d. n.d. 
3 
 
64.8 ± 1.5 
57.7  
[47.1–70.8] 
16.0  
[13.0–19.6] 
4 
 
65.6 ± 3.3 
48.9  
[41.9–57.0] 
13.5  
[11.6–15.8] 
5 
 
62.0 ± 1.5 
51.3  
[41.3–63.8] 
15.1  
[12.2– 8.8] 
6 
 
<1 n d. n.d. 
7 
 
69.0 ± 12.4 
53.0  
[43.8–64.0] 
13.8  
[11.4–16.7] 
8 
 
<1 n.d. n.d. 
9 
 
38.5 ± 2.9 n.d. n.d. 
10 c 
 
23.3 ± 9.6 n.d. n.d. 
1 
 
9.8 ± 6.7 n.d. n.d. 
12 c 
 
>99 
30.7  
[27.0–35.0] 
9.0  
[7.9–10.3]. 
13 c 
 
>99 
8.1  
[6.8–9.6] 
2.4  
[2.0 2.8] > 9 . [6.8–9.6] 2.4 [2.0–2.8]
14 c
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 c 
 
63.6 ± 6.8 
39.2  
[2 .8 57.4] 
11.5  
[7.9–16. ] 
15 
 
<1 n.d. n.d. 
16 c 
 
91.9 ± 8.2 
10.8  
[9.3–12.5] 
3.2  
[2.7–3.7] 
17 
 
11.0 ± 3.9 n.d. n.d. 
18 c 
 
34.1 ± 7.5 n.d. n.d. 
19 
 
5.9 ± 5.7 n.d. n.d. 
20 c 
 
81.5 ± 4.7  
16.8  
[13.6–20.6] 
4.9  
[4.0–6.0] 
21 c 
 
96.5 ± 1.4 
12.6  
[10.6–15.1] 
3.7  
[3.1–4.4] 
22 c 
 
<1 n.d. n.d. 
23 
 
4.6 ± 13.8 n.d. n.d. 
24 c 
 
72.0 ± 9.8 
43.8  
[30.6–62.7] 
12.8  
[9.0–18.4] 
25 c 
 
81.3 ± 17.0 
26.3  
[19.6–35.4] 
7.7  
[5.7–10.4] 
6.8 39.2 [26.8–57.4] 11.5 [7.9–16.8]
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Table 1. Cont.
Compound Structure Inhibition (%)[at 100 µM] IC50 [µM]
a,b IC50 [µg/mL] a,b
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14 c 
 
63.6 ± 6.8 
39.2  
[26.8–57.4] 
11.5  
[7.9–16.8] 
15 
 
<1 n.d. n.d. 
16 c 
 
91.9 ± 8.2 
10.8  
[9.3–12.5] 
3.2  
[2.7–3.7] 
17 
 
11.0 ± 3.9 n.d. n.d. 
18 c 
 
34.1 ± 7.5 n.d. n.d. 
19 
 
5.9 ± 5.7 n.d. n.d. 
20 c 
 
81.5 ± 4.7  
16.8  
[13.6–20.6] 
4.9  
[4.0–6.0] 
21 c 
 
96.5 ± 1.4 
12.6  
[10.6–15.1] 
3.7  
[3.1–4.4] 
22 c 
 
<1 n.d. n.d. 
23 
 
4.6 ± 13.8 n.d. n.d. 
24 c 
 
72.0 ± 9.8 
43.8  
[30.6–62.7] 
12.8  
[9.0–18.4] 
25 c 
 
81.3 ± 17.0 
26.3  
[19.6–35.4] 
7.7  
[5.7–10.4] 
< n.d. n.d.
16 c
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14 c 
 
63.6 ± 6.8 
39.2  
[26.8–57.4] 
11.5  
[7.9–16.8] 
15 
 
<1 n.d. n.d. 
16 c 
 
91.9 ± 8.2 
10.8  
[9.3–12.5] 
3.2  
[2.7–3.7] 
17 
 
11.0 ± 3.9 n.d. n.d. 
18 c 
 
34.1 ± 7.5 n.d. n.d. 
19 
 
5.9 ± 5.7 n.d. n.d. 
20 c 
 
81.5 ± 4.7  
16.8  
[13.6–20.6] 
4.9  
[4.0–6.0] 
21 c 
 
96.5 ± 1.4 
12.6  
[10.6–15.1] 
3.7  
[3.1–4.4] 
22 c 
 
<1 n.d. n.d. 
23 
 
4.6 ± 13.8 n.d. n.d. 
24 c 
 
72.0 ± 9.8 
43.8  
[30.6–62.7] 
12.8  
[9.0–18.4] 
25 c 
 
81.3 ± 17.0 
26.3  
[19.6–35.4] 
7.7  
[5.7–10.4] 
. 8.2 10.8 [9.3–12.5] 3.2 [2.7–3.7]
17
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14 c 
 
63.6 ± 6.8 
39.2  
[26.8–57.4] 
11.5  
[7.9–16.8] 
15 
 
<1 n.d. n.d. 
16 c 
 
91.9 ± 8.2 
10.8  
[9.3–12.5] 
3.2  
[2.7–3.7] 
 
 
11.0 ± 3.9 n.d. n.d. 
18 c 
 
34.1 ± 7.5 n.d. n.d. 
19 
 
5.9 ± 5.7 n.d. n.d. 
20 c 
 
81.5 ± 4.7  
16.8  
[13.6–20.6] 
4.9  
[4.0–6.0] 
21 c 
 
96.5 ± 1.4 
12.6  
[10.6–15.1] 
3.7  
[3.1–4.4] 
22 c 
 
<1 n.d. n.d. 
23 
 
4.6 ± 13.8 n.d. n.d. 
24 c 
 
72.0 ± 9.8 
43.8  
[30.6–62.7] 
12.8  
[9.0–18.4] 
25 c 
 
81.3 ± 17.0 
26.3  
[19.6–35.4] 
7.7  
[5.7–10.4] 
. 3.9 n.d. n.d.
18 c
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14 c 
 
63.6 ± 6.8 
39.2  
[26.8–57.4] 
11.5  
[7.9– 6.8] 
15 
 
<1 n.d. n.d. 
16 c 
 
91.9 ± 8.2 
10.8  
[9.3–12.5] 
3.2  
[2.7–3.7] 
17 
 
11.0 ± 3.9 n.d. n.d. 
 c 
 
34.1 ± 7.5 n.d. n.d. 
19 
 
5.9 ± 5.7 n.d. n.d. 
20 c 
 
81.5 ± 4.7  
16.8  
[13.6–20.6] 
4.9  
[4.0–6.0] 
21 c 
 
96.5 ± 1.4 
12.6  
[10.6–15.1] 
3.7  
[3.1–4.4] 
22 c 
 
<1 n.d. n.d. 
23 
 
4.6 ± 13.8 n.d. n.d. 
24 c 
 
72.0 ± 9.8 
43.8  
[30.6–62.7] 
12.8  
[9.0–18.4] 
25 c 
 
81.3 ± 17.0 
26.3  
[19.6–35.4] 
7.7  
[5.7–10.4] 
7.5 n.d. n.d.
19
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14 c 
 
63.6 ± 6.8 
39.2  
[26.8–57.4] 
11.5  
[7.9–16.8] 
15 
 
<1 n.d. n.d. 
16 c 
 
91.9 ± 8.2 
10.8  
[9.3–12.5] 
3.2  
[2.7–3.7] 
17 
 
11.0 ± 3.9 n.d. n.d. 
18 c 
 
34.1 ± 7.5 n.d. n.d. 
 
 
5.9 ± 5.7 n.d. n.d. 
20 c 
 
81.5 ± 4.7  
16.8  
[13.6–20.6] 
4.9  
[4.0–6.0] 
21 c 
 
96.5 ± 1.4 
12.6  
[10.6–15.1] 
3.7  
[3.1–4.4] 
22 c 
 
<1 n.d. n.d. 
23 
 
4.6 ± 13.8 n.d. n.d. 
24 c 
 
72.0 ± 9.8 
43.8  
[30.6–62.7] 
12.8  
[9.0–18.4] 
25 c 
 
81.3 ± 17.0 
26.3  
[19.6– 5.4] 
7.7  
[5.7–10.4] 
. 5.7 n.d. n.d.
20 c
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14 c 
 
63.6 ± 6.8 
39.2  
[26.8–57.4] 
11.5  
[7.9–16.8] 
15 
 
<1 n.d. n.d. 
16 c 
 
91.9 ± 8.2 
10.8  
[9.3–12.5] 
3.2  
[2.7–3.7] 
17 
 
11.0 ± 3.9 n.d. n.d. 
18 c 
 
34.1 ± 7.5 n.d. n.d. 
19 
 
5.9 ± 5.7 n.d. n.d. 
  
 
81.5 ± 4.7  
16.8  
[13.6–20.6] 
4.9  
[4.0–6.0] 
21 c 
 
96.5 ± 1.4 
12.6  
[10.6–15.1] 
3.7  
[3.1–4.4] 
22 c 
 
<1 n.d. n.d. 
23 
 
4.6 ± 13.8 n.d. n.d. 
24 c 
 
72.0 ± 9.8 
43.8  
[30.6–62.7] 
12.8  
[9.0–18.4] 
25 c 
 
81.3 ± 17.0 
26.3  
[19.6–35.4] 
7.7  
[5.7–10.4] 
. 4.7 16.8 [13.6–20.6] 4.9 [4.0–6.0]
21 c
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14 c 
 
63.6 ± 6.8 
39.2  
[26.8–57.4] 
11.5  
[7.9–16.8] 
15 
 
<1 n.d. n.d. 
16 c 
 
91.9 ± 8.2 
10.8  
[9.3–12.5] 
3.2  
[2.7–3.7] 
17 
 
11.0 ± 3.9 n.d. n.d. 
18 c 
 
34.1 ± 7.5 n.d. n.d. 
19 
 
5.9 ± 5.7 n.d. n.d. 
20 c 
 
81.5 ± 4.7  
16.8  
[13.6–20.6] 
4.9  
[4.0–6.0] 
  
 
96.5 ± 1.4 
12.6  
[10.6–15.1] 
3.7  
[3.1–4.4] 
22 c 
 
<1 n.d. n.d. 
23 
 
4.6 ± 13.8 n.d. n.d. 
24 c 
 
72.0 ± 9.8 
43.8  
[30.6–62.7] 
12.8  
[9.0–1 .4] 
25 c 
 
81.3 ± 17.0 
26.3  
[19.6–35.4] 
7.7  
[5.7–10.4] 
. 1.4 12.6 [10.6–15.1] 3.7 [3.1–4.4]
22 c
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14 c 
 
63.6 ± 6.8 
39.2  
[26.8–57.4] 
11.5  
[7.9–16.8] 
15 <1 n.d. n.d. 
6 c 
 
91.9 ± 8.2 
10.8  
[9.3–12.5] 
3.2  
[2.7–3.7] 
17 
 
1 0  3.9 n.d. n.d. 
8 c 
 
34.1  7.5 . . . . 
19 
 
5.9  5.7 . . . . 
20 c 
 
81.5 ± 4.7  
16.8  
[13.6–20.6] 
4.9  
[4.0–6.0] 
1 c 
 
96.5 ± 1.4 
2.6  
[ 0. 15.1] 
3.7  
[3.1 4.4] 
 c 
 
<1 n.d. n.d. 
3 
 
4.6 ± 13.8 . . . . 
4 c 
 
72.0 ± 9.  
43.8  
[30.6–62.7] 
12.8  
[9.0–18.4] 
5 c 
 
81.3  17.0 
26.3  
[19. 35.4] 
7.7  
[5.7 0. ] 
1 n.d. n.d.
23
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14 c 
 
63.6 ± 6.8 
39.2  
[26.8–57.4] 
11.5  
[7.9–16.8] 
15 
 
<1 n.d. n.d. 
16 c 
 
91.9 ± 8.2 
10.8  
[9.3–12.5] 
3.2  
[2.7–3.7] 
17 
 
11.0 ± 3.9 n.d. n.d. 
18 c 
 
34.1 ± 7.5 n.d. n.d. 
19 
 
5.9 ± 5.7 n.d. n.d. 
20 c 
 
81.5 ± 4.7  
16.8  
[13.6–20.6] 
4.9  
[4.0–6.0] 
21 c 
 
96.5 ± 1.4 
12.6  
[10.6–15.1] 
3.7  
[3.1–4.4] 
22 c 
 
<1 n.d. n.d. 
 
 
4.6 ± 13.8 n.d. n.d. 
24 c 
 
72.0 ± 9.8 
43.8  
[30.6–62.7] 
12.8  
[9.0–18.4] 
25 c 
 
81.3 ± 17.0 
26.3  
[19.6–35.4] 
7.7  
[5.7–10.4] 
13.8 n.d. n.d.
24 c
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14 c 
 
63.6 ± 6.8 
39.2  
[26.8–57.4] 
11.5  
[7.9– 6.8] 
15 <1 n.d. n.d. 
16 c 
 
91.9 ± 8.2 
10.8  
[9.3–12.5] 
3.2  
[2.7–3.7] 
17
 
11.0 ± 3.9 n.d. n.d. 
18 c 
 
34.1 ± 7.5 n.d. n.d. 
19
 
5.9 ± 5.7 n.d. n.d. 
20 c 
 
81.5 ± 4.7  
16.8  
[13.6–20.6] 
4.9  
[4.0–6.0] 
21 c 
 
96.5 ± 1.4 
12.6  
[10.6–15.1] 
3.7  
[3.1–4.4] 
22 c 
 
<1 n.d. n.d. 
23
 
4.6 ± 13.8 n.d. n.d. 
24 c 
 
72.0 ± 9.8 
43.8  
[30.6–62.7] 
12.8  
[9.0–18.4] 
25 c 
 
81.3 ± 17.0 
26.3  
[19.6–35.4] 
7.7  
[5.7–10.4] 
72.0 ± 9.8 43.8 [30.6–62.7] 12.8 [9.0–18.4]
25 c
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[9.3–12.5] 
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81.5 ± 4.7  
16.8  
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[4.0–6.0] 
21 c 
 
96.5 ± 1.4 
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[10.6–15.1] 
3.7  
[3.1–4.4] 
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<1 n.d. n.d. 
23 
 
4.6 ± 13.8 n.d. n.d. 
24 c 
 
72.0 ± 9.8 
43.8  
[30.6–62.7] 
12.8  
[9.0–1 .4] 
 c 
 
81.3 ± 17.0 
2 .3  
[19.6–35.4] 
7.7  
[5.7–10.4] . 17.0 26.3 [19.6–35.4] 7.7 [5.7–10.4]
26 c
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63.9 ± 3.4 
36.8  
[29.2–46.3] 
10.8  
[8.6–13.6] 
27 
 
<1 n.d. n.d. 
28 
 
99.1 ± 0.7 
55.9  
[50.9–61.3] 
27.7  
[25.2–30.4] 
29 
 
17.8 ± 4.1 n.d. n.d. 
30 
 
9.5 ± 4.8 n.d. n.d. 
31 
 
97.3 ± 0.5 
12.0  
[9.3–15.6] 
3.5  
[2.7–4.6] 
32 
 
<1 n.d. n.d. 
33 
 
<1 n.d. n.d. 
34 
 
37.9 ± 5.2 n.d. n.d. 
35 13.9 ± 3.6 n.d. n.d. 
36 
 
<1 n.d. n.d. 
37 
 
<1 n.d. n.d. 
63.9 . 36.8 [29.2–46.3] 10.8 [8.6–13.6]
27
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37 
 
<1 n.d. n.d. 
n.d. n.d.
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Table 1. Cont.
Compound Structure Inhibition (%)[at 100 µM] IC50 [µM]
a,b IC50 [µg/mL] a,b
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26 c 
 
63.9 ± 3.4 
36.8  
[29.2–46.3] 
10.8  
[8.6–13.6] 
27 
 
<1 n.d. n.d. 
28 
 
99.1 ± 0.7 
55.9  
[50.9–61.3] 
27.7  
[25.2–30.4] 
 
 
17.8 ± 4.1 n.d. n.d. 
30 
 
9.5 ± 4.8 n.d. n.d. 
31 
 
97.3 ± 0.5 
12.0  
[9.3–15.6] 
3.5  
[2.7–4.6] 
32 
 
<1 n.d. n.d. 
33 
 
<1 n.d. n.d. 
34 
 
37.9 ± 5.2 n.d. n.d. 
35 13.9 ± 3.6 n.d. n.d. 
36 
 
<1 n.d. n.d. 
37 
 
<1 n.d. n.d. 
17.8 ± n.d. n.d.
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27 
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99.1 ± 0.7 
55.9  
[50.9–61.3] 
27.7  
[25.2–30.4] 
29 
 
17.8 ± 4.1 n.d. n.d. 
30 
 
9.5 ± 4.8 n.d. n.d. 
31 
 
97.3 ± 0.5 
12.0  
[9.3–15.6] 
3.5  
[2.7–4.6] 
32 
 
<1 n.d. n.d. 
33 
 
<1 n.d. n.d. 
34 
 
37.9 ± 5.2 n.d. n.d. 
35 13.9 ± 3.6 n.d. n.d. 
36 
 
<1 n.d. n.d. 
37 
 
<1 n.d. n.d. 
9.5 ± 4.8 n.d. n.d.
31
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55.9  
[50.9–61.3] 
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[25.2–30.4] 
29 
 
17.8 ± 4.1 n.d. n.d. 
30 
 
9.5 ± 4.8 n.d. n.d. 
 
 
97.3 ± 0.5 
12.0  
[9.3–15.6] 
3.5  
[2.7–4.6] 
32 
 
<1 n.d. n.d. 
33 
 
<1 n.d. n.d. 
34 
 
37.9 ± 5.2 n.d. n.d. 
35 13.9 ± 3.6 n.d. n.d. 
36 
 
<1 n.d. n.d. 
37 
 
<1 n.d. n.d. 
. 0.5 12.0 [9.3–15.6] 3.5 [2.7–4.6]
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63.9 ± 3.4 
36.8  
[29.2–46.3] 
10.8  
[8.6–13.6] 
27 
 
<1 n.d. n.d. 
28 
 
99.1 ± 0.7 
55.9  
[50.9–61.3] 
27.7  
[25.2–30.4] 
29 
 
17.8 ± 4.1 n.d. n.d. 
30 
 
9.5 ± 4.8 n.d. n.d. 
31 
 
97.3 ± 0.5 
12.0  
[9.3–15.6] 
3.5  
[2.7–4.6] 
 
 
<1 n.d. n.d. 
33 
 
<1 n.d. n.d. 
34 
 
37.9 ± 5.2 n.d. n.d. 
35 13.9 ± 3.6 n.d. n.d. 
36 
 
<1 n.d. n.d. 
37 
 
<1 n.d. n.d. 
n.d. n.d.
33
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63.9 ± 3.4 
36.8  
[29.2–46.3] 
10.8  
[8.6–13.6] 
27 
 
<1 n.d. n.d. 
28 
 
99.1 ± 0.7 
55.9  
[50.9–61.3] 
27.7  
[25. –30.4] 
29 
 
17.8 ± 4.1 n.d. n.d. 
30 
 
9.5 ± 4.8 n.d. n.d. 
31 
 
97.3 ± 0.5 
12.0  
[9.3–15.6] 
3.5  
[2.7–4.6] 
32 
 
<1 n.d. n.d. 
 
 
<1 n.d. n.d. 
34 
 
37.9 ± 5.2 n.d. n.d. 
35 13.9 ± 3.6 n.d. n.d. 
36 
 
<1 n.d. n.d. 
37 
 
<1 n.d. n.d. 
n.d. n.d.
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63.9 ± 3.4 
36.8  
[29.2–46.3] 
10.8  
[8.6–13.6] 
27 
 
<1 n.d. n.d. 
28 
 
99.1 ± 0.7 
55.9  
[50.9–61.3] 
27.7  
[25.2–30.4] 
29 
 
17.8 ± 4.1 n.d. n.d. 
30 
 
9.5 ± 4.8 n.d. n.d. 
31 
 
97.3 ± 0.5 
12.0  
[9.3–15.6] 
3.5  
[2.7–4.6] 
32 
 
<1 n.d. n.d. 
33 
 
<1 n.d. n.d. 
 
 
37.9 ± 5.2 n.d. n.d. 
35 13.9 ± 3.6 n.d. n.d. 
36 
 
<1 n.d. n.d. 
37 
 
<1 n.d. n.d. 
37.9 . n.d. n.d.
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26 c 
 
63.9 ± 3.4 
36.8  
[29.2–46.3] 
10.8 
[8.6–13.6] 
27 
 
<1 n.d. n.d. 
28 
 
99.  ± 0.7 
55.9  
[50.9–61.3] 
27.7  
[25.2–30.4] 
29 
 
17.8 ± 4.1 n.d. n.d. 
30 
 
9.5 ± 4.8 n.d. n.d. 
31 
 
97.3 ± 0.5 
12.0  
[9.3–15.6] 
3.5  
[2.7–4.6] 
32 
 
<1 n.d. n.d. 
33 
 
<1 n.d. n.d. 
4 
 
37.9 ± 5.2 n.d. n.d. 
35 13.9 ± 3.6 n.d. n.d. 
36 
 
<1 n.d. n.d. 
37 
 
<1 n.d. n.d. 
13.9 ± 3.6 n.d. n.d.
36
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26 c 
 
63.9 ± 3.4 
36.8  
[29.2–46.3] 
10.8  
[8.6–13.6] 
27 
 
<1 n.d. n.d. 
28 
 
99.1 ± 0.7 
55.9  
[50.9–61.3] 
27.7  
[25.2–30.4] 
29 
 
17.8 ± 4.1 n.d. n.d. 
30 
 
9.5 ± 4.8 n.d. n.d. 
1 
 
7.3 ± 0.5 
12.0  
[9.3–15.6] 
3.5  
[2.7–4.6] 
32 
 
<1 n.d. n.d. 
33 
 
<1 n.d. n.d. 
34 
 
37.9 ± 5.2 n.d. n.d. 
35 13.9 ± 3.6 n.d. n.d. 
 
 
<1 n.d. n.d. 
37 
 
<1 n.d. n.d. 
n.d. n.d.
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26 c 
 
63.9 ± 3.4 
36.8  
[29.2–46.3] 
10.8  
[8.6– 3.6] 
27 
 
<1 n.d. n.d. 
28 
 
99.1 ± 0.7 
55.9  
[50.9–61 3] 
27.7  
[25.2–30 4] 
29 
 
17.8 ± 4.1 n.d. n.d. 
30 
 
9.5 ± 4.8 . . . . 
31 
 
97.3 ± 0.5 
12.0  
[9.3– 5.6]
3.5  
[2.7–4.6]
2 
 
<1 n.d. n.d  
33 
 
<1 . . . . 
34 
 
37.9 ± 5.2 . . . . 
35 13.9 ± 3.6 . . . . 
36 
 
<1 . . . . 
 
 
<1 . . . . n.d. n.d.
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38 
 
46.3 ± 3.7 n.d. n.d. 
39 
 
<1 n.d. n.d. 
40 
 
<1 n.d. n.d. 
Licochalcone d   62.5–150 18.3–44.0 
FLC  n.d. 
0.25  
[0.18–0.33] 
0.07  
[0.05–0.1] 
a IC50 is defined as the concentration giving rise to an inhibition of growth of 50% compared to the 
drug-free control. b Data are reported as mean values and 95% confidence interval. c See [17]. d See [16], 
FLC, fluoconazole; n.d., not determined. 
2.3.2. Cytotoxicity Assay 
Fungi and mammalian cells share analogous cellular and biochemical pathways; thus, an ideal 
antifungal agent should be devoid of unwanted side effects. In light of the liabilities of the chalcone 
scaffold [23], our sixteen best-performing compounds were tested on mammalian epithelial cells 
(Vero) treated for 72 h with different concentrations of chalcones (200‒6.25 μM range), and cell 
viability was evaluated. Table 2 reports CC50 values in both μM and in μg/mL. This cytotoxicity assay 
allows us to establish whether the observed effect is associated with a specific ability to affect fungal 
growth and not purely linked to a general toxic effect. 
In particular, compounds 4, 5, 14, and 28 did not display any toxicity, as they did not interfere 
at all with Vero metabolism, even at the highest concentration of 200 μM. In addition, compounds 1, 
3, and 7, showing triple-digit micromolar CC50 values (174.1 μM, 151.8 μM, and 181.7 μM, 
respectively), only slightly affected eukaryotic cell growth, and could therefore be considered non-
toxic. 
Analogue 20 was moderately toxic (CC50 = 54.3 μM); nevertheless, its good antifungal effect (IC50 
= 16.8 μM) somewhat counterbalances this drawback and, generally, for this compound, an 
acceptable host/fungi selectivity profile could be assumed. Altogether, these results point to 20 as a 
promising compound worth modifying to decrease the toxicity.  
Conversely, compounds 13, 16, 21, 24–26, and 31 were associated with a certain degree of toxicity 
since they showed CC50 values in the micromolar range that were not significantly different from the 
IC50 values on C. albicans. Therefore, their activity on yeast growth could be considered a generic 
cytotoxic effect, thus precluding any further investigation.  
Overall, considering that all compounds belonging to Series I were non-toxic, its key chemical 
features, namely the 2-hydroxy-5-halo substitution pattern of the A-ring, coupled with fluorine 
decoration of the B-ring, are expected to lead to effective antifungal agents.  
Moreover, analogues 28 and 31, both bearing a 4-F aryl ring, showed the opposite behavior. The 
measured toxic effects could be ascribed to the decoration pattern of the A-ring. This trend is also 
found for the couple 14/31 endowed with a 4-nitrophelyl moiety and differing from the substituent 
appended at the 2-position (methoxy/propargiloxy).  
Since analogues 1, 3–5, 7, 14, and 28 displayed a good safety profile, they were considered for 
additional evaluations regarding their antimicrobial profile. Their IC50 values are comparable to those 
measured for the lichochalcone A over different strains of C. albicans in a recently published paper 
. 3.7 n.d. n.d.
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found for the couple 14/31 endowed with a 4-nitrophelyl moiety and differing from the substituent 
appended at the 2-position (methoxy/propargiloxy).  
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a IC50 is defined as the concentration giving rise to an inhibition of growth of 50% compared to the drug-free control.
b Data are reported as mean values and 95% confidence interval. c See [17]. d See [16], FLC, fluoconazole; n.d.,
not determined.
2.3.2. Cytotoxicity Assay
Fungi and mammalian c lls share analogous cellular and biochemical pathways; thus, an ideal
antifungal agent should be devoid of unwanted side effects. In light of the liabilities of the chalcone
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scaffold [23], our sixteen best-performing compounds were tested on mammalian epithelial cells (Vero)
treated for 72 h with different concentrations of chalcones (200-6.25 µM range), and cell viability was
evaluated. Table 2 reports CC50 values in both µM and in µg/mL. This cytotoxicity assay allows us to
establish whether the observed effect is associated with a specific ability to affect fungal growth and
not purely linked to a general toxic effect.
Table 2. Cytotoxicity of selected chalcone-based analogues against Vero cells (CC50 values are expressed
in µM and µg/mL).
Compound CC50 [µM] a,b CC50 [µg/mL] a,b
1 174.1 [157.0–193.1] 45 [40.6–50.0]
3 151.8 [131.7–175.0] 42.0 [36.4–48.4]
4 >200 >55.3
5 >200 >58.9
7 181.7 [126.3–261.4] 47.3 [32.9–68.0]
12 13.6 [12.7–14.6] 4.0 [3.7–4.3]
13 7.3 [6.2–8.7] 2.1 [1.8–2.5]
14 >200 >58.6
16 17.8 [15.8–20.1] 5.2 [4.6–5.9]
20 54.3 [50.3–58.5] 15.9 [14.8–17.2]
21 14.8 [13.7–16.0] 4.3 [4.0–4.7]
24 13.0 [11.4–14.8] 3.8 [3.3–4.3]
25 9.1 [8.6–9.8] 2.7 [2.5–2.9]
26 5.1 [4.7–5.5] 1.5 [1.4–1.6]
28 >200 >99.2
31 8.3 [7.1–9.6] 2.4 [2.1–2.8]
a CC50 is defined as the concentration giving rise to an inhibition of growth of 50% compared to untreated Vero cells.
b Data are reported as mean values and 95% confidence interval.
In particular, compounds 4, 5, 14, and 28 did not display any toxicity, as they did not interfere at
all with Vero metabolism, even at the highest concentration of 200 µM. In addition, compounds 1, 3,
and 7, showing triple-digit micromolar CC50 values (174.1 µM, 151.8 µM, and 181.7 µM, respectively),
only slightly affected eukaryotic cell growth, and could therefore be considered non-toxic.
Analogue 20 was moderately toxic (CC50 = 54.3 µM); nevertheless, its good antifungal effect
(IC50 = 16.8 µM) somewhat counterbalances this drawback and, generally, for this compound,
an acceptable host/fungi selectivity profile could be assumed. Altogether, these results point to
20 as a promising compound worth modifying to decrease the toxicity.
Conversely, compounds 13, 16, 21, 24–26, and 31 were associated with a certain degree of toxicity
since they showed CC50 values in the micromolar range that were not significantly different from
the IC50 values on C. albicans. Therefore, their activity on yeast growth could be considered a generic
cytotoxic effect, thus precluding any further investigation.
Overall, considering that all compounds belonging to Series I were non-toxic, its key chemical
features, namely the 2-hydroxy-5-halo substitution pattern of the A-ring, coupled with fluorine
decoration of the B-ring, are expected to lead to effective antifungal agents.
Moreover, analogues 28 and 31, both bearing a 4-F aryl ring, showed the opposite behavior.
The measured toxic effects could be ascribed to the decoration pattern of the A-ring. This trend is also
found for the couple 14/31 endowed with a 4-nitrophelyl moiety and differing from the substituent
appended at the 2-position (methoxy/propargiloxy).
Since analogues 1, 3–5, 7, 14, and 28 displayed a good safety profile, they were considered for
additional evaluations regarding their antimicrobial profile. Their IC50 values are comparable to those
measured for the lichochalcone A over different strains of C. albicans in a recently published paper [16],
again confirming chalcone as a privileged scaffold, suitable for the development of antifungal agents.
The above in vitro toxicity evaluation demonstrated some liabilities of the chalcone scaffold and
helped us to gain insight into the chemical features affecting or modulating toxic effects. Of note, the
pyridine as B-ring undoubtedly represents an issue that needs to be addressed in designing the next
generation of derivatives.
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2.3.3. Inhibition of Candida spp. and non-Candida Yeasts
After we assessed the selective inhibition of chalcones 1, 3–5, 7, 14, and 28 over C. albicans
ATCC 10231, we further assayed them towards seven clinical isolates of Candida spp. and three
non-Candida yeasts (Tables 3 and 4, respectively). The C. albicans strain recovered from a clinical
specimen displayed a susceptibility profile similar to that defined for the control strain, with some
slight differences regarding compounds 3 and 5. This confirms the need to include in the antifungal
screening not only standard strains with a stable, defined phenotype and genotype, but also clinical
isolates that are representative of pathogens circulating in the population [24]. Moreover, all the
selected compounds showed antifungal activity against C. lusitaniae, even if to a different extent, and a
good effect was observed for 3, 4, 7, and 28. On the contrary, compounds 1, 4, 14, and 28 proved to
inhibit C. utilis growth, with 14 and 28 being the most potent, while only 3 and 28 affected C. parapsilosis
growth. Among the tested clinical strains, C. krusei, C. glabrata, and C. tropicalis exhibited the most
resistant phenotypes, only being susceptible to chalcone 28. This is a promising result as the two latter
non-Candida species account for the majority of all the infections not caused by C. albicans and their
increasing resistance to the azole drug class is of great concern. In addition, chalcone 28 exhibited
a similar inhibitory activity compared to FLC for C. krusei and against some clinical isolates IC50
values were around 25 µM. These values perfectly comply with the criteria suggested by Cos et al. [24]
defining the anti-infective potential of a small molecule.
Table 3. Antifungal effect determined for compounds 1, 3-5, 7, 14, 28 and for the control FLC against
various Candida spp. The activities are expressed as IC50 values a,b [µM (above) and in µg/mL (below)].
Compound C. albicans C. parapsilosis C. lusitaniae C. tropicalis C. krusei C. glabrata C. utilis
1
62.9
[45.9–79.8] 200 100 200 200 200
84.5
[77.5–92.2]
16.3
[11.9–20.6] 51.7 25.9 51.7 51.7 51.7
21.9
[20.0–23.9]
3
100 41.5[27.2–63.1]
38.5
[29.7–50.0] >200 >200 >200 100
27.7 11.5[7.5–17.5]
10.7
[8.2–13.8] >55.3 >55.3 >55.3 27.7
4
69.6
[51.7–93.7] >200
34.6
[21.5–55.8] 200 200 200
96.7
[90.8–102.9]
19.3
[14.3–25.9] >55.3
9.6
[5.9–15.4] 55.3 55.3 55.3
26.8
[25.1–28.5]
5
100 200 47.9[37.2–61.9] >200 >200 >200 100
29.5 58.9 14.1[11.0–18.2] >58.9 >58.9 >58.9 29.5
7
32.1
[26.4–39.0] 100
31.7
[26.3–38.1] >200 100 100 100
8.4
[6.9–10.1] 26.0
8.2
[6.8–9.9] >52.0 26.0 26.0 26.0
14
31.4
[25.5–40.2] 100
48.8
[28.3–66.4] 200 200 200
33.7
[27.8–40.8]
10.6
[21.1–19.9] 33.7
14.8
[9.6–22.4] 67.5 67.5 67.5
11.4
[9.4–13.8]
28
48.1
[41.2–56.0]
36.8
[30.2–44.8]
26.5
[19.9–35.2]
26.6
[24.1–29.3]
63.5
[59.1–68.3]
37.1
[31.7–43.5]
29.6
[27.0–32.4]
23.9
[20.4–27.8]
18.3
[15.0–22.2]
13.1
[9.9–17.5]
13.2
[12.0–14.5]
31.5
[29.3–33.9]
18.4
[15.7–21.6]
14.7
[13.4–16.1]
FLC
0.42
[0.29–0.61]
0.037
[0.02–0.07]
0.05
[0.01–0.2] 0.40
64.6
[44.3–94.2]
14.4
[12.6–16.4]
1.56
[0.96–2.53]
0.13
[0.09–0.19]
0.01
[0.01–0.02]
0.015
[0.003–0.06] (0.31–0.52)
19.8
[13.6–28.9]
4.4
[3.9–5.0]
0.5
[0.3–0.8]
a IC50 value is defined as the concentration giving rise to an inhibition of growth of 50% compared to the drug-free
control. b Data are reported as mean values and 95% confidence interval.
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The potency of chalcone 28 is also demonstrated by the distinctive sigmoidal form of the
dose-response curves (Figure 2 and Table S1). Curves reached 100% of response, indicating its efficacy
to completely inhibit yeast growth, and the steep slopes suggested its high effectiveness against the
tested strains, as small increases in the doses corresponded to great responses. Just as exceptions, the
efficacy of chalcone 28 was slightly lower towards C. parapsilosis and C. lusitaniae compared to the
other clinical isolates, and a shallower curve with a lower slope factor was generated.
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Con erning the activity of the seven selected analogues against the other clinically relevant yeasts,
they exhibited an overall strong inhibitory effect on C. neoformans and R. mucilaginosa compared
to FLC (Table 4). Chalcones 5, 7, and 28 displayed potent two-digit micromolar IC50 values on
the C. neoformans isolate, indicating a potentially relevant clinical impact; indeed, infections by this
opportunistic pathogen give rise to most cases of AIDS-related meningitis worldwide, and there has
been an i crease i the percentage of Cryptococcus isolates found to have some degree of FLC resistance.
Chalcone 28 exhibited a ainst this pathogen the same potency and efficacy observed for t e ot er
tested Candida spp. isolates (Figure S1 and Table S2).
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Table 4. Antifungal effect determined for compounds 1, 3-5, 7, 14, 28 and for the control FLC against
various non-Candida yeast strains. The activities are expressed as IC50 values a,b [µM (above) and in
µg/mL (below)].
Compound C. neoformans S. clavata R. mucilaginosa
1
26.4 [22.6–30.9] 200 83.7 [70.1–100.0]
6.8 [5.8–8.0] 51.7 21.7 [18.1–25.9]
3
35.2 [31.7–39.0] 37.2 [30.9–44.9] >200
9.7 [8.8–10.8] 10.3 [8.5–12.4] 55.3
4
27.1 [22.5–32.7] 200 81.8 [75.1–89.0]
7.5 [6.2–9.0] 55.3 22.6 [20.8–24.6]
5
18.0 [15.9–40.5] 100 76.9 [63.5–93.1]
5.3 [4.7–11.9] 29.5 22.7 [18.7–27.4]
7
15.6 [14.0–16.9] 37.0 [26.9–50.9] 80.0 [71.5–89.5]
4.1 [3.6–4.4] 9.6 [7.0–13.2] 20.8 [18.6–23.3]
14
28.4 [22.6–35.6] 100 100
9.6 [7.6–12.0] 33.7 33.7
28
17.7 [15.6–20.0] 27.9 [22.2–35.0] 48.5 [42.1–50.9]
8.8 [7.7–9.9] 13.8 [11.0–17.4] 21.4 [20.9–25.2]
FLC
255.9 [93.68–699] 0.04 [0.01–0.08] 1605 [549–4694]
78.4 [28.7–214.1] 0.012 [0.003–0.025] 491 [168–1437]
a,b IC50 value is defined as the concentration giving rise to an inhibition of growth of 50% compared to the drug-free
control. Data are reported as mean values and 95% confident interval.
2.3.4. Inhibition of Yeast-to-Hyphae Morphological Transition
The ability of the seven chalcones to weaken microbial virulence was further investigated in
C. albicans ATCC 10231. A key virulence factor expressed by C. albicans that significantly contributes
to its pathogenicity is the transition of yeast cells to filamentous cells. The formation of germ tube
and mycelium is an essential process for host tissue invasion, damage to mucosal epithelia, escape
from host immune cells, and blood dissemination. Additionally, the conversion of C. albicans from
yeast to hyphae is related to the expression of specific adhesins that are involved in the formation of
biofilms [4]. For this purpose, C. albicans was cultured for 2 h in an RPMI-1640 medium supplemented
with serum at 10% and containing the chalcones 1, 3–5, 7, 14, and 28 at IC50 values, and then evaluated
for their effect on hyphae formation.
As presented in Figure 3, untreated cells exhibited a prevalence of branched filamentous cells,
while cells treated with the compounds at IC50 values showed different morphological forms with
blastospores, budding cells, and filamentous cells. The ranking of yeast-to-hyphae inhibition,
as determined by the visual observation of cultures, was 1 < 28 < 14 < 4 < 5 < 3 < 7. In particular, the
C. albicans control strain treated with chalcone 7 mainly formed blastospores, some rare budding cells
but no hyphae; thus, 7 interfered in vitro with the morphological plasticity of C. albicans, which is a
crucial virulence determinant for epithelial and endothelial invasion and accession to the bloodstream.
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Figure 3. Structural framework of C. albicans ATCC 10231 grown for 2 h in RPMI1640-FCS culture
medium containing chalcones at IC50 values. Visual differences in cell morphotypes can be observed
among the positive untreated control and cells at the different experimental conditions. DMSO was
used at 0.5% as the solvent control and it did not affect hyphal transition.
2.3.5. Inhibition of C. albicans Fila entation in y hal-Inducing Media
In order to further support the activity of some selected chalcones against virulence attributes
of C. albicans ATCC 10231 the standard test simulating the filamentation into the tissue (i.e., “Spider”
agar assay) was carried out and results are shown in Figure 4. Filaments (hyphae/pseudohyphae)
seen under a light microscope at the edge of the colonies in the control medium and in the solvent
control were large and formed a broad spider-branched zone around the mycelium. On the contrary,
C. albicans spotted on the Spider medium containing chalcones 5 and 7 at IC50 values were unable to
penetrate the medium and only blastospores were visualized in the dense mass of the colonies. These data
suggested that these compounds inhibit not only the first stage of hyphal growth involving the production
of germ tube and hyphae, but also the ability of C. albicans to invade a solid medium in the long term.
Molecules 2018, 23, x FOR PEER REVIEW  14 of 27 
 
In order to further support the activity of some selected chalcones against virulence attributes of 
C. albicans ATCC 10231 the standard test simulating the filamentation into the tissue (i.e., “Spider” 
agar assay) was carried out and results are shown in Figure 4. Filaments (hyphae/pseudohyphae) 
seen under a light microscope at the edge of the colonies in the control medium and in the solvent 
control were large and formed a broad spider-branched zone around the mycelium. On the contrary, 
C. albicans spotted on the Spider medium containing chalcones 5 and 7 at IC50 values were unable to 
penetrate the medium and only blastospores were visualized in the dense mass of the colonies. These 
data suggested that these compounds inhibit not only the first stage of hyphal growth involving the 
production of germ tube and hyphae, but also the ability of C. albicans to invade a solid medium in 
the long term. 
 
Figure 4. Impact of chalcones 5 and 7 at IC50 values on C. albicans ATCC 10231 invasion potential 
determined in the Spider agar assay. The colony edges were imaged using a light microscope at the 
different experimental conditions. DMSO, used as control, did not interfere with C. albicans 
filamentation. The presence of pseudohyphal growth area at the colony edges was determined using 
a light microscope. 
2.3.6. Antibiofilm Activity 
Compelling evidences suggest biofilm formation is very often associated to C. albicans infections 
and is responsible for the therapeutic failure and/or resistance phenomena. Biofilms are complex 
functional communities of one or more species of microorganisms that are encapsulated in a matrix 
of extracellular polymeric substances. Their development is caused by the adhesion of the 
microorganisms community to a solid (inert or living) surface. Indeed, the formed biofilm being a 
complex matrix represents a serious virulence factor that is difficult to eradicate. This physical barrier 
hampers the antifungal agent from reaching the pathogens and exerting its activity. The antibiofilm 
effects of the most active compounds, also able to influence yeast morphogenesis (1, 3–5, 7, 14, and 
28), were investigated in vitro on C. albicans ATCC 10231, evaluating their ability to inhibit the biofilm 
formation process and/or disrupt a mature biofilm. In details, C. albicans cells were incubated in the 
presence of these compounds at IC50 values and, following a 24-h incubation, the biofilm mass was 
quantitatively evaluated by crystal violet staining and destaining solution that was measured 
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Figure 4. Impact of chalcones 5 and 7 at IC50 values on C. albicans ATCC 10231 invasion potential
determined in the Spider agar assay. The colony edges were imaged using a light microscope at
the different experimental conditions. DMSO, used as control, did not interfere with C. albicans
filamentation. The presence of pseudohyphal growth area at the colony edges as deter ined using a
light microscope.
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2.3.6. Antibiofilm Activity
Compelling evidences suggest biofilm formation is very often associated to C. albicans infections
and is responsible for the therapeutic failure and/or resistance phenomena. Biofilms are complex
functional communities of one or more species of microorganisms that are encapsulated in a
matrix of extracellular polymeric substances. Their development is caused by the adhesion of the
microorganisms community to a solid (inert or living) surface. Indeed, the formed biofilm being a
complex matrix represents a serious virulence factor that is difficult to eradicate. This physical barrier
hampers the antifungal agent from reaching the pathogens and exerting its activity. The antibiofilm
effects of the most active compounds, also able to influence yeast morphogenesis (1, 3–5, 7, 14, and 28),
were investigated in vitro on C. albicans ATCC 10231, evaluating their ability to inhibit the biofilm
formation process and/or disrupt a mature biofilm. In details, C. albicans cells were incubated in
the presence of these compounds at IC50 values and, following a 24-h incubation, the biofilm mass
was quantitatively evaluated by crystal violet staining and destaining solution that was measured
spectrophotometrically. As reported in Figure 5, even if the solvent contributed to the inhibition,
all tested compounds were able to effectively reduce the formation of the biofilm mass with the
following order of potency: 3 > 4 ~ 7 ~ 5 ~ 14 ~ 28 > 1. This effect could be ascribed to the change
in cell wall components that is critical for C. albicans adhesion to surfaces; indeed, chalcones may act
towards fungal cells by interfering with different biosynthesis, all contributing to disrupt the fungal
cell wall [25].
In parallel, the selected compounds were added to a preformed mature biofilm of C. albicans and
their effect was expressed as the reduction of the biofilm metabolic activity. The data shown in Figure 5
demonstrated that only two molecules (5 and 7) slightly diminished the metabolism of sessile cells,
at a statistically significant level, even if to a minimal extent (<25%). As currently available antifungals
have marginal effect against biofilms [26], the activities of these chalcones are therefore of relevance,
and new therapeutic agents targeting biofilms are desperately needed, mainly for the treatment of
persistent device-associated infections. Interestingly, chalcone 7 displayed remarkable antifungal
activity, specifically against C. albicans, affecting several virulence factors: yeast growth, germ tube
formation, and biofilm production. In addition, among the seven active compounds, it exhibited the
greatest inhibitory activity against the clinical isolate of C. albicans (IC50 = 32.1 µM).
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chalcones 1, 3–5, 7, 14, and 28 vs. DMSO/positive control. Biofilm disruption: * p < 0.05 for chalcones 
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(right panel). Values are reported as mean ± SD. Biofilm formation: *** p < 0.0005 for chalcones 1,
3–5, 7, 14, and 28 vs. DMSO/positive control. Biofil disruption: * p < 0.05 for chalcones 5 and 7 vs.
DMSO/positive control. The negative control consists of the medium only.
3. Discussion
A small library of 40 chalcone-based analogues was evaluated for their antifungal potential.
The study delivered three lead molecules (28, 5, and 7) endowed with releva t antifungal features.
Analogue 28 proved to be the ost interesting since it exhibited a broad spectrum of activity, being
able to effectively inhibit several Candida spp. such as C. albicans, C. parapsilosis, C. lusitaniae, C. krusei,
C. tropicalis, C. glabrata, and C. utilis, and a broad array of clinically relevant yeasts, including
C. neoformans, which is responsible of one of the most fatal me ingoencephalitis in AIDS patients
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across the globe. The concomitant presence of the phenylpiperazine, protonable at physiological pH,
and the 4-F-phenyl moiety could be responsible for the good antifungal effect of this chalcone.
The antifungal effect of compounds 5 and 7 could mainly be ascribed to an antivirulence effect;
as they weakened hyphae and biofilm production, factors strongly involved in C. albicans pathogenesis,
this behavior perfectly meets the current paradigm of anti-infective therapeutics [27]. The presence of
a halogen (chlorine or fluorine atom) in the 5-position of the chalcone A-ring seems to be a favorable
substitution pattern.
Overall, the pyridine heterocycle as B-ring demonstrated to confer an impressive ability to inhibit
C. albicans growth; unfortunately, this effect is likely due to the intrinsically toxic effects of the molecules.
However, this last sub-set represents a promising starting point in optimization efforts. In fact, we
anticipate that it will be possible to overcome the current drawbacks by proper functionalization of the
heterocyclic nitrogen atom.
4. Experimental Section
4.1. Chemistry
Starting materials, unless otherwise specified, were used as high-grade commercial products.
Solvents were of analytical grade. Reaction progress was followed by thin-layer chromatography (TLC)
on precoated silica gel plates (Merck Silica Gel 60 F254, Darmstadt, Germany) and then visualized
with a UV 254 lamplight. Chromatographic separations were performed on Merck silica gel columns
by the flash method (Kieselgel 40, 0.040–0.063 mm, Merck, Darmstadt, Germany). Melting points were
determined in open glass capillaries, using a Büchi SMP-20 apparatus (Büchi Italia s.r.l., Cornaredo,
Mi, Italy) and are uncorrected. 1H-NMR and 13C-NMR spectra were recorded on a Varian Gemini
spectrometer (Scientific instruments, Palo Alto, CA, USA) 400 MHz and 101 MHz, respectively,
and chemical shifts (δ) are reported as parts per million (ppm) values relative to tetramethylsilane
(TMS) as internal standard; unless otherwise indicated, CDCl3 was used as the solvent. Standard
abbreviations indicating spin multiplicities are given as follows: s (singlet), d (doublet), t (triplet),
br (broad), q (quartet), or m (multiplet); coupling constants (J) are reported in Hertz (Hz). Mass
spectra were recorded on a Waters ZQ 4000 apparatus Waters Alliance, San Diego, CA, USA) operating
in electrospray mode (ES). Analyses indicated by the symbols of the elements were within ± 0.4%
of the theoretical values. Compounds were named relying on the naming algorithm developed
by CambridgeSoft Corporation and used in Chem-BioDraw Ultra 14.0 (PerkinElmer Inc., Waltham,
MA, USA).
4.1.1. Williamson Reaction: General Procedure
A mixture of the selected acetophenone (1.0 eq), alkyl halide (1.0 or 1.1 eq), K2CO3 (1.0 eq) in
acetone was heated under reflux for 6–10 h; reaction progress was monitored by TLC. Upon reaction
completion, the mixture was hot filtered and the solvent was evaporated under reduced pressure.
The resulting crude product was purified by column chromatography using a mixture of petroleum
ether (PE)/ethyl acetate (EtOAc) as eluent to give the desired pure product.
1-(4-(2-chloroethoxy)-2-hydroxyphenyl)ethan-1-one (46). Reaction of 2,4-dihydroxyacetophenone (0.76 g,
5.0 mmol) and 1-bromo-2-chloroethane (0.94 g, 0.45 mL, 5.0 mmol) gave a crude product that was
purified by column chromatography (PE/EtOAc 4:1) producing 46 as a solid (0.55 g), 85% yield.
1H-NMR δ 2.60 (s, 3H, COCH3), 3.83 (t, 2H, J = 6.0 Hz, CH2Cl), 4.26 (t, 2H, J = 6.0 Hz, OCH2), 6.40 (d,
J = 2.2 Hz, 1H, H-3) 6.48 (dd, J = 8.0 and 2.2 Hz, 1H, rH-5), 7.65 (d, 1H, J = 9.2 Hz, H-6). 13 C-NMR δ
26.3, 60.55, 69.21, 103.25, 106.74, 131.00, 165.47, 165.87, 201.88.
1-(4-(2-chloroethoxy)-2-methoxyphenyl)ethan-1-one (47). Reaction of 43 (0.18 g, 0.87 mmol) and methyl
iodide (0.14 g, 0.06 mL, 0.96 mmol) gave a crude product that was purified by column chromatography
(PE/AcOEt 9:1) producing 47 as a transparent oil (0.13 g), 78% yield. 1H-NMR δ 2.65 (s, 3H, COCH3),
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3.85 (t, 2H, J = 6.0 Hz, CH2Cl), 3.96 (s, 3H, OCH3), 4.30 (t, 2H, J = 6.0 Hz, OCH2), 6.50 (d, J = 2.2 Hz, 1H,
H-3) 6.58 (dd, J = 8.0 and 2.2 Hz, 1H, H-5), 7.67 (d, 1H, J = 9.2 Hz, H-6). 13 C-NMR δ 26.10, 42.54, 45.97,
75.44, 101.23, 106.78, 119.84, 130.67, 161.74, 164.74, 199.55.
1-(4-(2-hydroxyethoxy)phenyl)ethan-1-one (50). Reaction of 4-hydroxyacetophenone (5.0 mmol, 0.90 g)
and 2-bromoethanol (5.5 mmol, 0.68 g) gave the crude final product that was purified by column
chromatography (PE/EtOAc 4:1) to produce 50 as a white solid (0.63 g), 75% yield. 1H-NMR (acetone
d6) δ 2.58 (s, 3H, CH3), 3.92–3.98 (m, 2H, CH2OH), 4.07 (t, J = 4.4 Hz, 1H, OH), 4.15 (t, J = 6.4 Hz, 2H,
OCH2), 6.96 (d, J = 8.6 Hz, 2H, H-3 and H-5), 7.96 (d, J = 8.8 Hz, 2H, H-2 and H-6). 13 H-NMR δ 26.88,
64.22, 69.15, 127.42, 128.75, 129.12, 129.66, 166.84, 198.05.
1-(4-((3-methylbut-2-en-1-yl)oxy)phenyl)ethan-1-one (51). Reaction of 4-hydroxyacetophenone (0.76 g,
5.0 mmol) and 3,3-dimethylallylbromide (0.82 g, 5.5 mmol) gave a crude final product that was purified
by column chromatography (PE/EtOAc 9:1) to produce 51 as a transparent oil (0.97 g), 95% yield.
1H-NMR δ 1.78 (s, 3H, CH3), 1.79 (s, 3H, CH3), 2.54 (s, 3H, COCH3), 4.57 (d, J = 6.8 Hz, 2H, OCH2), 5.47
(t, J = 6.8 Hz, 1H, =CH), 6.92 (d, J = 8.8 Hz, 2H, H-3 and H-5), 7.92 (d, J = 7.2 H-2 and H-6). 13C-NMR δ
18.1, 25.7, 26.1, 64.9, 114.2, 118.9, 130.1, 130.4, 138.7, 162.7, 196.6. 13 C-NMR δ 18.88, 26.55, 64.58, 114.47,
114.97, 12.032, 129.16, 129.74, 130.54, 138.17, 162.28, 198.27.
1-(4-(prop-2-yn-1-yloxy)phenyl)ethan-1-one (52). Reaction of 4-hydroxyacetophenone (0.76 g, 5.0 mmol)
and propargyl bromide solution 80 wt % in toluene (0.80 g, 5.5 mmol) gave the crude final product that
was purified by column chromatography (PE/EtOAc 9:1) to produce 52 as a solid (0.90 g), 93% yield,
mp: 73–74 ◦C. 1H-NMR δ 2.54-2.56 (m, 4H, CH and COCH3), 4.76 (d, J = 4.2 Hz, 2H, OCH2), 7.01 (dd,
J = 2.0 and 8.0 Hz, 2H, H-3 and H-5), 6.95 (dd, J = 2.0 and 8.0 Hz, 2H, H-2 and H-6). 13 C-NMR δ 26.33,
56.47. 78.91, 79.32, 114.21, 114.51, 129.06, 129.48, 162.47, 198.41.
1-(2-Methoxy-4-(2-(4-phenylpiperazin-1-yl)ethoxy)phenyl)ethan-1-one (48). A mixture of 47 (0.26 g, 1.0 mmol),
phenylpiperazine (0.24 g, 1.5 mmol) and TEA (0.21 mL, 1.5 mmol) in THF was stirred at rt for 18 h.
The solvent was removed by evaporation under reduced pressure and the crude was purified by
column chromatography (DCM/MeOH/NH4OH 9.5:0.45:0.05) to give 48 as a dense oil (0.30 g), 87%
yield; hydrochloride salt mp 131-132 ◦C. 1H-NMR δ 2.50 (s, 3H, COCH3), 2.72-2.76 (m, 4H, piperazine),
2.90 (t, J = 5.6 Hz, 2H, NCH2), 3.22-3.25 (m, 4H, piperazine), 4.19 (t, J = 5.6 Hz, 2H, OCH2), 6.45 (d,
J = 1.2 Hz, 1H, H-3), 6.48 (dd, J = 8.4 and 1.2 Hz, 1H, H-5), 6.89 (t, J = 8.4 Hz, 1H, H-4′), 6.94 (d,
J = 8.4 Hz, 2H, H-2′ and H-6′), 7.24-7.26 (m, 2H, H-3′ and H-5′), 7.64 (d, J = 8.4 Hz, 1H, H-6), 12.7 (s, 1H,
OH). 13 C-NMR δ 26.53, 49.27, 53.81, 57.03, 56.11, 66. 48, 101.67, 108.21, 114.19, 116.25, 119.95, 129.27,
132.45, 151.40, 195.36.
1-(4-((1-(2-hydroxyethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methoxyphenyl)ethan-1-one (49). A mixture of
45 (0.15 g, 0.73 mmol), 2-azidoethan-1-ol (0.08 g, 0.95 mmol), CuSO4 (0.02 g), Na-ascorbate (0.07 g,
0.37 mmol) in DMSO (6.0 mL) was stirred at room temperature for 8 h. Then the mixture was poured
in H2O and extracted with EtOAc (12 mL × 3). The combined organic layers were dried over Na2SO4,
filtered and the solvent was removed under reduced pressure. The crude was purified by column
chromatography (PE/AcOEt 7:3) producing 49 as an oily product (0.19 g), 98% yield. 1H-NMR δ 2.61
(s, 3H, COCH3), 2.95 (br, 1H, OH), 3.87 (s, 3H, OCH3), 4.07 (t, J = 5.2 Hz, 2H, NCH2), 4.51 (t, J = 5.2 Hz,
2H, OCH2), 5.23 (s, 2H, OCH2), 6.56 (d, J = 2.4 Hz, 1H, H-3), 6.60 (dd, J = 2.4 and 7.6 Hz, 1H, H-5), 7.78
(s, 1H, triazole CH), 7.79 (d, J = 8.0 Hz, 1H, H-6). 13 C-NMR δ 26.21, 54.57, 55.08, 60.01, 72.94, 101.24,
106.74, 119.84, 128.45, 131.19, 162.32, 166.82. 194.21.
4.1.2. Claisen–Schmidt Reaction: General Procedure
Route A. To a solution of the selected acetophenone (1.0 eq) and aldehyde (1.1 eq) in EtOH (10 mL)
a KOH aqueous solution (50% p/v, 1 mL) was added dropwise and reaction mixture was stirred
overnight at rt, diluted with H2O, and neutralized with aqueous 6N HCl. The formed solid/semisolid
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product was collected by vacuum filtration or extracted with a suitable solvent. The crude of reaction
was then purified by column chromatography or by crystallization.
Route B. To a solution the selected acetophenone (1.0 eq) and aldehyde (1.1 eq) in EtOH (10 mL),
a solution of piperidine (0.5 mL) and acetic acid (0.3 mL) in EtOH (1 mL) was added. The reaction
mixture was heated under reflux for 12–18 h and the reaction progress was monitored by TLC.
The solvent was removed under reduced pressure and the crude of reaction was purified by column
chromatography or crystallization.
Route C. A mixture the selected acetophenone (1.0 eq) and aldehyde (1.1 eq) in EtOH (10 mL),
Ba(OH)2 (3.3 eq) was added. The reaction mixture was stirred at rt overnight; then diluted with H2O
and neutralized with aqueous 6N HCl. The formed solid/semisolid product was collected by vacuum
filtration or extracted with a suitable solvent. The crude of reaction was then purified by column
chromatography or by crystallization.
(E)-1-(5-Chloro-2-hydroxyphenyl)-3-phenylprop-2-en-1-one (1). Following route A, and starting from
5′-chloro-2′-hydroxyacetophenone (0.17 g, 1.0 mmol) and benzaldehyde (0.12 g, 1.1 mmol) a solid
product was obtained that was collected by vacuum filtration. The crude of reaction was purified by
crystallization from EtOH producing 1 as a yellowish solid (0.22 g), 85% yield, mp 97–98 ◦C. 1H-NMR δ
6.98 (d, J = 8.4 Hz, 1H, H-3), 7.43 (dd, J = 1.2 and 8.4 Hz, 2H), 7.33–7.38 (m, 2H, H-3′-H5′), 7-50–7.54 (m,
2H, H-2′ and H-6′), 7.60 (d, J = 16.0 Hz, 1H, β-CH=), 7.86 (1H, d, J = 1.2 Hz, H-6), 8.04 (d, J = 15.6 Hz,
1H, α-CH=), 12.55 (br, 1H, OH). 13C-NMR δ 119.21, 124.45, 127.21, 128.75, 128.77, 130.76, 131.32, 137.14,
145.16, 161.08, 192.11. ESI-MS (m/z) 259 (M + 1). HRMS ESI + [M + 1]: calcd for C15H11ClO2, 259.0526.
Found: 259.0528.
(E)-1-(5-Chloro-2-hydroxyphenyl)-3-(2-fluorophenyl)prop-2-en-1-one (2). Following route A, and starting
from 5′-chloro-2′-hydroxyacetophenone (0.17 g, 1.0 mmol) and 2-fluorobenzaldehyde (0.14 g, 1.1 mmol),
a solid product was obtained that was collected by vacuum filtration and crystallized from EtOH,
producing 2 as a white solid (0.13 g), 47% yield, mp 86–87 ◦C. 1H-NMR δ 7.00 (d, J = 8.8 Hz, 1H, H-3),
7.15–7.20 (m, 1H, Ar), 7.46–7.48 (m, 2H, Ar), 7.67–7.72 (m, 2H, Ar), 7.70 (d, J = 16.0 Hz, 1H, β-CH=),
7.76–7.86 (m, 1H, Ar), 8.04 (d, J = 15.6 Hz, 1H, α-CH=), 12.67 (br, 1H, OH). 13C-NMR δ 115.16, 119.45,
121.21, 123.11, 124.25, 128.27, 128.75, 131.86, 137.32, 145.16, 161.58, 192.31. ESI-MS (m/z): 399 (M+23).
HRMS ESI + [M + 1]: calcd for C15H10ClFO2, 277.0431. Found: 277.04533.
(E)-1-(5-Chloro-2-hydroxyphenyl)-3-(3-fluorophenyl)prop-2-en-1-one (3). Following route A, and starting
from 5′-chloro-2′-hydroxyacetophenone (0.17 g, 1.0 mmol) and 3-fluorobenzaldehyde (0.14 g,
1.1 mmol), a solid product was obtained that was collected by vacuum filtration, purified by column
chromatography (PE/EtOAc 9.5:0.5), and crystallized from EtOH, producing 3 as a yellowish solid
(0.13 g), 46% yield, mp 75–77 ◦C. 1H-NMR δ 7.02 (d, J = 8.8 Hz, 1H, H-5), 7.14-7.17 (m, 1H, Ar), 7.37–7.44
(m, 3H, Ar), 7.49 (dd, J = 2.4 and 8.8 Hz, 1H, H-4), 7.57 (d, J = 15.2 Hz, 1H, β-CH=), 7.87 (d, J = 2.4 Hz,
1H, H-6), 7.91 (d, J = 15.2 Hz, 1H, α-CH=). 13C-NMR δ 113.26, 114.45, 119.91, 123.81, 124.28, 127.77,
130.20, 131.86, 136.22, 161.16, 162.58, 192.51. ESI-MS (m/z) 277 (M + 1). HRMS ESI + [M + 1]: calcd for
C15H10ClFO2, 277.0431. Found: 277.0432.
(E)-1-(5-Chloro-2-hydroxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one (4). Following route A, and starting
from 5′-chloro-2′-hydroxyacetophenone (0.17 g, 1.0 mmol) and 4-fluorobenzaldehyde (0.14 g, 1.1 mmol),
a solid product was obtained that was collected by vacuum filtration and crystallized from EtOH,
to obtain 4 as a white solid (0.21 g), 75% yield, mp 79–81 ◦C. 1H-NMR δ 6.99 (d, J = 8.8 Hz, 1H, H-5),
7.13 (d, J = 8.8 Hz, 1H, H-3′), 7.15 (d, J = 8.8 Hz, 1H, H-5′), 7.45 (dd, J = 2.4 and 8.8 Hz, 1H, H-4) 7.49 (d,
J = 15.2 Hz, 1H, β-CH=), 7.68 (d, J = 8.4 Hz, 1H, H-2′), 7.69 (d, J = 8.8 Hz, 1H, H-6′), 7.80 (d, J = 2.4 Hz,
1H, H-6), 7.92 (d, J = 15.2 Hz, 1H, α-CH=). 13C-NMR δ 116.25, 116.47, 119.19, 120.29, 120.54, 123.57,
128.75, 130.85 136.14, 145.16, 162.08, 192.64. ESI-MS (m/z) 277 (M + 1). HRMS ESI + [M + 1]: calcd for
C15H10ClFO2, 277.0431. Found: 277.0433.
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(E)-1-(5-Chloro-2-hydroxyphenyl)-3-(3,5-difluorophenyl)prop-2-en-1-one (5). Following route A, and starting
from 5′-chloro-2′-hydroxyacetophenone (0.17 g, 1.0 mmol) and 3,5-di-fluorobenzaldehyde (0.16 g,
1.1 mmol), a solid product was obtained that was collected by vacuum filtration and crystallized from
EtOH, to obtain 5 as a white solid (0.20 g), 67% yield, mp 102–103 ◦C. 1H-NMR δ 6.92 (t, J = 8.4 Hz 1H,
H-4′), 7.02 (d, J = 9.2 Hz, 1H, H-3), 7.20 (d, J = 6.0 Hz, 2H, H-2′ and H-6′), 7.48 (dd, J = 2.0 and 8.8 Hz,
1H, H-4), 7.55 (d, J = 15.6 Hz, 1H, β-CH=), 7.85 (s, 1H, H-6), 7.83 (d, J = 15.6 Hz, 1H, α-CH=), 12.98 (br,
1H, OH). 13C-NMR δ 103.25, 109.47, 119.33, 124.29, 127.53, 130.57, 131.75, 137.14, 138.99, 160.68, 192.33.
ESI-MS (m/z) 295 (M + 1). HRMS ESI + [M + 1]: calcd for C15H9ClF2O2, 295.0337. Found: 295.0339.
(E)-1-(5-chloro-2-hydroxyphenyl)-3-(4-(dimethylamino)phenyl)prop-2-en-1-one (6). Following route B, and
starting from 5′-chloro-2′-hydroxyacetophenone (0.17 g, 1.0 mmol) and 4-(dimethylamino)benzaldehyde
(0.16 g, 1.1 mmol), a crude of reaction was obtained purified by column chromatography (PE/EtOAc
7:3), and crystallized from EtOH to obtain 6 as a red solid (0.20 g), 67% yield, mp 125–127 ◦C. 1H-NMR
δ 3.10 (s, 6H, CH3), 6.79 (d, J = 8.4 Hz, 2H, H-2′ and H-6′), 6.97 (d, J = 9.2 Hz, 1H, H-3), 7.38 (d,
J = 15.2 Hz, 1H, β-CH=), 7.41 (dd, J = 2.4 and 8.8 Hz, 1H, H-4), 7.62 (d, J = 8.4 Hz, 2H, H-3′ and H-5′),
7.88 (d, J = 2.8 Hz, 1H, H-6), 7.95 (d, J = 14.8 Hz, 1H, α-CH=), 13.10 (br, 1H, OH). 13C-NMR δ 40.08,
111.77, 113.41, 120.01, 121.03, 122.05, 123.15, 128.52, 131.14, 135.31, 147.58, 152.54, 161.94. ESI-MS (m/z)
302 (M + 1). HRMS ESI + [M + 1]: calcd for C17H16ClNO2, 302.0948. Found: 302.0950.
(E)-1-(5-Fluoro-2-hydroxyphenyl)-3-(3-fluorophenyl)prop-2-en-1-one (7). Following route A, and starting
from 5′-fluoro-2′-hydroxyacetophenone (0.15 g, 1.0 mmol) and 3-fluorobenzaldehyde (0.14 g, 1.1 mmol),
a solid product was obtained that was collected by vacuum filtration and crystallized from EtOH to
obtain 7 as a white solid (0.18 g), 70% yield, mp 92–94 ◦C. 1H-NMR δ 7.00–7.04 (m, 1H, Ar), 7.15–7.19
(m, 1H, Ar), 7.26–7.25 (m, 1H, Ar), 7.37–7.39 (m, 1H, Ar), 7.41–7.45 (m, 2H, Ar), 7.54 (d, J = 15.6 Hz, 1H,
β-CH=), 7.56–7.29 (m, 1H), 7.90 (d, J = 15.2 Hz, 1H, α-CH=). 13C-NMR δ 110.22, 114.44, 118.29, 120.29,
123.44, 123.56, 125.57, 130.45, 136.14, 145.76, 159.11, 162.08, 192.67. ESI-MS (m/z) 261 (M + 1). HRMS
ESI + [M + 1]: calcd for C15H10F2O2, 261.0727. Found: 261.0725.
(E)-1-(5-Fluoro-2-hydroxyphenyl)-3-(4-fluorophenyl)prop-2-en-1-one (8). Following route A, and starting
from 5′-fluoro-2′-hydroxyacetophenone (0.15 g, 1.0 mmol) and 4-fluorobenzaldehyde (0.14 g, 1.1 mmol),
a semisolid product was obtained that was extracted with DCM (3× 30 mL). The unified organic layers
were dried over anhydrous Na2SO4 and evaporated to dryness to give a crude that was purified by
column chromatography (PE/EtOAc 95:0.5) and then crystallized from EtOAc/n-hexane, to produce 8
as a white solid (0.21 g), 80% yield, mp 94–96 ◦C. 1H-NMR δ 7.02 (dd, J = 8.8 and 9.6 Hz, 1H, H-3), 7.17
(d, J = 8.4 Hz, 1H, H-3′), 7.18 (d, J = 8.4 Hz, 1H, H-5′), 7.23-7.26 (m, 1H, H-4), 7.48 (d, J = 15.2 Hz, 1H,
β-CH=), 7.58 (dd, J = 2.4 and 8.8 Hz, 1H, H-6), 7.68 (d, J = 8.8 Hz, 1H, H-2′), 7.69 (d, J = 8.4 Hz, 1H,
H-6′), 7.92 (d, J = 15.2 Hz, 1H, α-CH=), 12.55 (s, 1H, OH). 13C-NMR δ 116.26, 116.67, 119.21, 120.27,
120.76, 123.69, 128.69, 130.23, 136.44, 159.90, 162.69, 192.44. ESI-MS (m/z) 261 (M + 1). HRMS ESI +
[M + 1]: calcd for C15H10F2O2, 261.0727. Found: 261.0728.
(E)-3-(4-(Dimethylamino)phenyl)-1-(5-fluoro-2-hydroxyphenyl)prop-2-en-1-one (9). Following route B, and
starting from 5′-fluoro-2′-hydroxyacetophenone (0.15 g, 1.0 mmol) and 4-(dimethylamino)benzaldehyde
(0.16 g, 1.1 mmol) a crude of reaction was obtained, purified by column chromatography (PE/EtOAc
7:3), and crystallized from EtOH to obtain 9 as a red solid (0.14 g), 50% yield, mp 131–135 ◦C. 1H-NMR
δ 3.09 (s, 6H, CH3), 6.75 (d, J = 9.2 Hz, 2H, H-3′ and H-5′), 6.97 (dd, J = 8.8 and 8.8 Hz, 1H, H-3), 7.24
(dd, J = 7.6 and 8.8 Hz, 1H, H-4), 7.34 (d, J = 15.2 Hz, 1H, β-CH=), 7.57–7.60 (m, 3H, H-6, H-3′, and
H-5′), 7.94 (d, J = 15.2 Hz, 1H, α-CH=), 12.89 (s, 1H, OH). 13C-NMR δ 41.35, 110.41, 117.55, 117.23,
124.78, 125.88, 145.21, 150.61, 159.41, 159.95, 193.57. ESI-MS (m/z) 286 (M + 1). HRMS ESI + [M + 1]:
calcd for C17H16FNO2, 286.1243. Found: 286.1244.
(E)-3-(4-fluorophenyl)-1-(2-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (10). Following route A,
and starting from 45 (0.20 g, 1.0 mmol) and 4-fluorobenzaldehyde (0.14 g, 1.1 mmol), a semisolid
product was obtained that was extracted with EtOAc (3 × 30 mL). The unified organic layers were
Molecules 2019, 24, 372 19 of 26
dried over anhydrous Na2SO4 and evaporated to dryness to give a crude that was purified by column
chromatography (PE/EtOAc 8:2), to produce 10 as a solid (0.29 g), 94% yield, mp 196–168 ◦C. 1H-NMR
δ 2.58 (t, J = 2.4 Hz, 1H, CH), 3.92 (s, 3H, OCH3), 4.77 (d, J = 2.0 Hz, 2H, OCH2), 6.61 (d, J = 2.0 Hz,
1H, H-3), 6.65 (dd, J = 2.4 and 8.8 Hz, 1H, H-5), 7.09 (d, J = 8.8 Hz, 1H, H-3′), 7.10 (d, J = 8.8 Hz, 1H,
H-6′), 7.43 (d, J = 16.0 Hz, 1H, β-CH=), 7.50-7.59 (m, 2H, H-2′ and H-6′), 7.65 (d, J = 16 Hz, 1H, α-CH=),
7.76 (d, J = 8.8 Hz, 1H, H-6). 13C-NMR δ 56.21, 76.54, 101.11, 107.45, 115.88, 118.66, 123.67, 130.11,
130.54, 131.87, 145.64, 162.46, 163.78, 188.32. ESI-MS (m/z) 311 (M + 1). HRMS ESI + [M + 1]: calcd for
C19H15FO3, 311.1083. Found: 311.1085.
(E)-3-(2,4-dichlorophenyl)-1-(2-methoxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (11). Following route
A, and starting from 45 (0.20 g, 1.0 mmol) and 2,4-dichlorobenzaldehyde (0.19 g, 1.1 mmol) a solid
product was obtained that was collected by vacuum filtration and crystallized from EtOH to give 11 as
a pale yellow solid (0.29 g), 84% yield, mp 174–75 ◦C. 1H-NMR δ 2.59 (t, J = 2.4 Hz, 1H, CH), 3.92 (s,
3H, OCH3), 4.78 (s, 2H, OCH2), 6.61 (d, J = 2.0 Hz, 1H, H-3), 6.66 (dd, J = 2.4 and 8.8 Hz, 1H, H-5), 7.28
(dd, J = 2.2 and 8.4 Hz 1H, H-5′), 7.45 (d, J = 2.2 Hz, 1H, H-3′), 7.47 (d, J = 16.0 Hz, 1H, β-CH=), 7.64 (d,
J = 8.8 Hz, 1H, H-6′), 7.79 (d, J = 8.8 Hz, 1H, H-6), 7.98 (d, J = 16.0 Hz, 1H, α-CH=). 13C-NMR δ 55.81,
56.71, 76.42, 77.66, 101.10, 107.54, 121.56, 122.47, 124.94, 125.98, 127.15, 129.74, 130.45, 1.3.31, 136.60,
161.74, 167.21, 194.11. ESI-MS (m/z) 361 (M+1). HRMS ESI + [M + 1]: calcd for C19H14Cl2O3, 361.0398.
Found: 361.0399.
(E)-3-(4-(dimethylamino)phenyl)-1-(2-methoxy-4-(prop-2-yn-1-yloxy) phenyl)prop-2-en-1-one (15). Following
route B, and starting from 45 (0.19 g, 1.0 mmol) 4-(dimethylamino)benzaldehyde (0.16 g, 1.1 mmol) a
crude of reaction was obtained that was purified by column chromatography (PE/EtOAc 7:3), and
crystallized from EtOH to obtain 15 as a red solid (0.20 g), 62% yield, mp 137–149 ◦C. 1H-NMR δ 2.57
(t, J = 2.4 Hz, 1H, CH), 3.04 (s, 6H, CH3), 3.89 (s, 3H, OCH3), 4.76 (d, J = 2.4 Hz, 2H, OCH2), 6.60
(s, 1H, H-3), 6.63 (dd, J= 2.4 and 10.4 Hz, 1H, H-5), 6.69 (d, J = 8.8 Hz, 2H, H-6′ and H-2′), 7.26 (d,
J = 15.6 Hz, 1H, β-CH=), 7.63 (d, J = 15.6 Hz, 1H, α-CH=), 7.69 (d, J = 8.8 Hz, 1H, H-6). 13C-NMR
δ 41.34, 56.18, 55.21, 76.44, 78.76, 101.38, 106,96, 111.15, 113.24, 118.91, 123.96, 124.99, 145.12, 152.45,
163.07, 166.21, 198.10. ESI-MS (m/z) 336 (M + 1). HRMS ESI + [M + 1]: calcd for C21H21NO3, 336.1599.
Found: 336.1597.
(E)-3-(4-(dimethylamino)phenyl)-1-(2-hydroxy-4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (17). Following
route B, and starting from 42 (0.20 g, 1.0 mmol) 4-(dimethylamino)benzaldehyde (0.16 g, 1.1 mmol),
a crude of reaction was obtained that was purified by column chromatography (PE/EtOAc 7:3), and
crystallized from EtOH to obtain 17 as a red solid (0.20 g), 62% yield, mp 137–149 ◦C. 1H-NMR δ 2.59
(t, J = 2.4 Hz, 1H, CH), 3.92 (s, 3H, OCH3), 4.78 (s, 2H, OCH2), 6.61 (d, J = 2.0 Hz, 1H, H-3), 6.66 (dd,
J = 2.4 and 8.8 Hz, 1H, H-5), 7.28 (dd, J = 2.2 and 8.4 Hz 1H, H-5′), 7.45 (d, J = 2.2 Hz, 1H, H-3′), 7.47 (d,
J = 16.0 Hz, 1H, β-CH=), 7.64 (d, J = 8.8 Hz, 1H, H-6′), 7.79 (d, J = 8.8 Hz, 1H, H-6), 7.98 (d, J = 16.0 Hz,
1H, α-CH=). 13C-NMR δ 55.81, 56.71, 76.42, 77.66, 101.10, 107.54, 121.56, 122.47, 124.94, 125.98, 127.15,
129.74, 130.45, 1.3.31, 136.60, 161.74, 167.21, 194.11. ESI-MS (m/z) 322 (M + 1). HRMS ESI + [M + 1]:
calcd for C20H19NO3, 322.1443. Found: 322.1445.
(E)-3-(2,4-dichlorophenyl)-1-(2-hydroxy-4-((3-methylbut-2-en-1-yl)oxy)phenyl)prop-2-en-1-one (19). Following
route A, and starting from 41 (0.22 g, 1.0 mmol) and 2,4-dichlorobenzaldehyde (0.19 g, 1.1 mmol) a
solid product was obtained that was collected by vacuum filtration and crystallized from EtOH to give
19 as a pale yellow solid (0.33 g), 88% yield, mp 191–93 ◦C. 1H-NMR δ 1.77 (s, 3H, CH3), 1.83 (s, 3H,
CH3), 4.59 (d, J = 6.8 Hz, 2H, OCH2), 5.50 (t, J = 6.8 Hz, 1H, CH), 6.51 (d, J = 7.2 Hz, 1H, H-5), 6.52 (s,
1H, H-3), 7.32 (dd, J = 2.2 and 6.8 Hz, 1H, H-5′), 7.50 (d, J = 2.0 Hz, 1H, H-3′), 7.69 (d, J = 8.8 Hz, 1H,
H-6′), 7.55 (d, J = 15.6 Hz, 1H, β-CH=), 7.80 (d, J = 9.2 Hz, 1H, H-6), 8.19 (d, J = 15.6 Hz, 1H, α-CH=),
13.3 (s, 1H, OH). 13C-NMR δ 18.23, 24.67, 64.64, 103.12, 107.75, 113.93, 119.45, 121.43, 124.11, 128.31,
130.00, 131.05, 131. 77, 138.54, 145.46, 165.92, 169.03, 194.34. ESI-MS (m/z) 377 (M + 1). HRMS ESI +
[M + 1]: calcd for C20H18Cl2O3, 377.0711. Found: 377.0713.
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(E)-1-(2,4-bis(prop-2-yn-1-yloxy)phenyl)-3-(2,4-dichlorophenyl)prop-2-en-1-one (23). Following route A, and
starting from 47 (0.23 g, 1.0 mmol) and 2,4-dichlorobenzaldehyde (0.19 g, 1.1 mmol) a solid product
was obtained that was collected by vacuum filtration and crystallized from EtOH to give 23 as a pale
yellow solid (0.30 g), 78% yield, mp 166–68 ◦C. 1H-NMR δ 2.58-2.62 (m, 2H, CH), 4.77 (d, J = 2.4 Hz,
2H, OCH2), 4.79 (d, J = 2.4 Hz, 2H, OCH2), 6.70 (d, J = 2.0 Hz, 1H, H-3), 6.73 (dd, J = 2.0 and 8.0 Hz,
1H, H-5), 7.26 (dd, J = 2.0 and 8.0 Hz, 1H, H-5′), 7.45 (d, J = 2.0 Hz, 1H, H-3′), 7.54 (d, J = 16.0 Hz,
1H, β-CH=), 7.70 (d, J = 8.4 Hz, 1H, H-6′), 7.82 (d, J = 8.4 Hz, 1H, H-6), 7.99 (d, J = 15.6 Hz, 1H,
α-CH=). 13C-NMR δ 56.44, 75.16, 78.92, 101.33, 107.21, 130.55, 121.98, 124.27, 126.19, 127.54, 128.23,
131.29, 137.37, 148.32, 162.62, 166.88, 193.71. ESI-MS (m/z) 385 (M + 1). HRMS ESI + [M + 1]: calcd for
C21H14Cl2O3, 385.0398. Found: 385.0398.
(E)-1-(2,4-bis(prop-2-yn-1-yloxy)phenyl)-3-(4-(dimethylamino)phenyl)prop-2-en-1-one (27). Following route
B, and starting from 47 (0.23 g, 1.0 mmol) and 4-(dimethylamino)benzaldehyde (0.16 g, 1.1 mmol),
a crude of reaction was obtained that was purified by column chromatography (PE/EtOAc 7:3), and
crystallized from EtOH to obtain to obtain 27 as a red solid (0.19 g), 55% yield, mp 127–129 ◦C. 1H-NMR
δ 2.56–2.61 (m, 2H, CH), 3.02 (s, 3H, CH3), 3.02 (s, 3H, CH3), 4.72–4.78 (m, 4H, OCH2), 6.53 (dd, J = 2.0
and 8.4 Hz, 1H, H-5), 6.56 (d, J = 2.4 Hz, 1H, H-3), 6.7(d, J = 8.4 Hz, 2H, H-3′ and H-5′), 7.36 (d,
J = 15.2 Hz, 1H, β-CH=), 7.58 (d, J = 8.4 Hz, 2H, H-2′ and H-6′), 7.87 (d, J = 8.8 Hz, 1H, H-6), 7.89 (d,
J = 15.2 Hz, 1H, α-CH=). 13C-NMR δ 41.41, 41.49, 56.43, 56.63, 76.11, 76.32, 78.78, 78.92, 101.33, 107.64,
111.32, 118.32, 118.54, 123.564, 124.32, 129.95, 131.12, 145.63, 151.01, 162.90, 165.17, 196.15. ESI-MS (m/z)
360 (M + 1). HRMS ESI + [M + 1]: calcd for C23H21NO3, 360.1599. Found: 360.1597.
(E)-3-(4-Fluorophenyl)-1-(2-methoxy-4-(2-(4-phenylpiperazin-1-yl)ethoxy)phenyl)prop-2-en-1-one (28). Following
route A, and starting from 48 (0.35 g, 1.0 mmol) and 4-fluorobenzaldehyde (0.14 g, 1.1 mmol),
a semisolid product was obtained that was extracted with DCM (3 × 30 mL). The unified organic
layers were dried over anhydrous Na2SO4 and evaporated to dryness to give a crude that was purified
by column chromatography (DCM/MeOH 95:5), to produce 28 as a semisolid product (0.15 g), 32%
yield, that was converted into the hydrochloride salt, mp 174–176 ◦C. 1H-NMR δ 3.41–3.45 (m, 2H,
piperazine), 3.61–3.45 (m, 2H, piperazine), 3.91–3.95 (m, 4H, piperazine), 3.96 (s, 3H, OCH3), 4.19
(t, J = 5.6 Hz, 2H, OCH2), 4.89(t, J = 5.6 Hz, 2H, NCH2), 6.55 (dd, J = 8.4 and 2.2 Hz, 1H, H-5), 6.62
(d, J = 2.2 Hz, 1H, H-3), 6.94–7.06 (m, 1H, Ph), 7.06–7.11 (m, 2H, Ph), 7.34–7.38 (m, 2H, Ph), 7.36 (d,
J = 15.6 Hz, 1H, β-CH=), 7.52–7.56 (m, 2H, H-2′ and H-6′), 7.61 (d, J = 15.6 Hz, 1H, α-CH=), 7.69 (d,
J = 8.8 Hz, 1H, H-6). 13C-NMR δ 49.27, 53.81, 57.03, 58.47, 66.49, 101.67, 108.12, 114.19, 116.25, 116.47,
119.94, 128.75, 129.26, 130.80, 136.24, 132.45, 145.16, 151.40, 165.36. ESI-MS (m/z) 461 (M + 1). HRMS
ESI + [M + 1]: calcd for C28H29FN2O3, 461.2240. Found: 461.2142.
(E)-3-(4-Fluorophenyl)-1-(4-hydroxy-2-methoxyphenyl)prop-2-en-1-one (29). Following route A, and starting
from 1-(4-hydroxy-2-methoxyphenyl)ethan-1-one (0.17 g, 1.0 mmol) and 4-fluorobenzaldehyde (0.14 g,
1.1 mmol), a semisolid product was obtained that was extracted with EtOAc (3 × 30 mL). The unified
organic layers were dried over anhydrous Na2SO4 and evaporated to dryness to give a crude that was
purified by column chromatography (PE/EtOAc 9:1), and crystallized from EtOH to produce 29 as a
solid (0.035 g), 13% yield, mp 166–168 ◦C. 1H-NMR δ 3.89 (s, 3H, OCH3). 6.50 (dd, J = 2.2 and 8.4 Hz,
1H, H-5), 6.51 (d, J =2.2 Hz, 1H, H-3), 7.06-7.10 (m, 2H, H-3′and H-5′), 7.44 (d, J = 16.0 Hz, 1H, β-CH=),
7.55-7.58 (m, 2H, H-2′ and H-6′), 7.61 (d, J = 16.0 Hz, 1H, β-CH=), 764 (d, J = 15.6 Hz, 1H, α-CH=), 7.69
(d, J = 8.8 Hz, 1H, H-6). 13C-NMR δ 102.64, 113.45, 115.24, 115.28, 118.67, 130.25, 130.56, 145.21, 162.49,
162.77, 165.45, 168.88. ESI-MS (m/z) 273 (M + 1). HRMS ESI + [M + 1]: calcd for C16H13FO3, 273.0927.
Found: 273.0925.
(E)-3-(4-fluorophenyl)-1-(4-((1-(2-hydroxyethyl)-1H-1,2,3-triazol-4-yl)methoxy)-2-methoxyphenyl)prop-2-en-1-one
(30). Following route A, and starting from 49 (0.29 g, 1.0 mmol) and 4-fluorobenzaldehyde (0.14 g,
1.1 mmol), a solid product was obtained that was collected by vacuum filtration and purified by
column chromatography (PE/EtOAc 1:1), to produce 30 as a white solid (0.079 g), 20% yield, mp
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100–102 ◦C. 1H-NMR δ 2.93 (br, 1H, OH), 3.88 (s, 3H, OCH3), 4.10 (t, J = 5.2 Hz, 2H, NCH2), 4.55
(t, J = 5.2 Hz, 2H, CH2OH), 5.21 (s, 2H, OCH2), 6.52 (d, J = 2.4 Hz, 1H, H-3), 6.62 (dd, J = 2.4 and 7.6 Hz,
1H, H-5), 7.42–7.49 (m, 2H, H-3′and H-5′), 7.60 (d, J = 15.6 Hz, 1H, β-CH=), 7.63–7.69 (m, 2H, H-2′
and H-6′), 7.80 (s, 1H, triazole CH), 7.74 (d, J = 15.6 Hz, 1H, α-CH=), (7.83 (d, J = 8.0 Hz, 1H, H-6).
13C-NMR δ 54.11, 55.64, 60.57, 72.12, 100.54, 105.21, 115.64, 115.74, 118.52, 123.77, 127.32, 130.47, 131.25,
131.55, 142.84, 145.37, 145.22, 162.34, 167.88, 195.94. ESI-MS (m/z) 398 (M + 1). HRMS ESI + [M + 1]:
calcd for C21H20FN3O4, 398.1516. Found: 398.1515.
(E)-3-(4-fluorophenyl)-1-(4-(2-hydroxyethoxy)phenyl)prop-2-en-1-one (31). Following route A, and starting
from 50 (0.18 g, 1.0 mmol) and 4-fluorobenzaldehyde (0.14 g, 1.1 mmol), a solid product was obtained
that was collected by vacuum filtration and purified by column chromatography (PE/EtOAc 4:1),
to produce 31 as a white solid (0.19 g), 67% yield. 1H-NMR (acetone d6) δ 3.92–3.96 (m, 2H, CH2OH),
4.02–4.04 (m, 1H, OH), 4.18 (t, J = 6.4 Hz, 2H, CH2O), 7.05 (d, J = 6.8 Hz, 2H, H-3 and H-5), 7.20 (t,
J = 8.8 Hz, 2H, H-3′ and H-5′), 7.72 (d, J = 15.6 Hz, 1H, β-CH=), 7.81 (d, J = 15.6 Hz, 1H, α-CH=),
7.83-7.88 (m, 2H, H-2′ and H-6′), 8.12 (d, J = 6.8 Hz, 2H, H-2 and H-6). 13C-NMR δ (acetone d6) 60.9,
69.9, 114.12, 116.80, 120.54, 129.65, 130.22, 130.97, 131.15, 131.45, 145.16, 160.21, 168. 01. ESI-MS (m/z)
287 (M + 1). HRMS ESI + [M + 1]: calcd for C17H15FO3, 287.1083. Found: 287.1085.
(E)-1-(4-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-(pyridin-3-yl)prop-2-en-1-one (32). Following Route C, and
starting from 51 (0.20 g, 1.0 mmol) and pyridine-3-carboxyaldehyde (0.12 g, 1.1 mmol) a solid product
was obtained that was collected by vacuum filtration and crystallized from EtOH to give 32 (0.17 g),
60% yield, mp 87–88 ◦C. 1H-NMR δ 1.78 (s, 3H, CH3), 1.83 (s, 3H, CH3), 4.62 (d, J = 6.8 Hz, 2H, OCH2),
5.11 (t, J = 1.2 Hz, 1H, CH), 7.01 (d, J = 8.8 Hz, 2H, H-3 and H-5), 7.35-7.39 (m, 1H, H-5′), 7.62 (d,
J = 15.6 Hz, 1H, β-CH=), 7.79 (d, J = 15.6 Hz, 1H, α-CH=), 7.95 (dd, J = 1.6 and 7.6 Hz, 1H, H-4′), 8.05
(d, J = 8.8 Hz, 2H, H-2 and H-6), 8.63 (dd, J = 1.6 and 7.6 Hz, 1H, H-4′), 8.87 (d, J = 2.0 Hz, 1H, H-2′).
13C-NMR δ 54.21, 55.87, 60.02, 72.15, 101.33, 105.74, 113.11, 118.21, 123.44, 128.64, 130.21, 130.31, 130.56,
131.64, 142.85, 162.18, 162.47. 163.54, 167.04, 195.32. ESI-MS (m/z) 294 (M + 1). HRMS ESI + [M + 1]:
calcd for C19H19NO2, 294.1494. Found: 294.1495.
(E)-1-(4-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-(pyridin-4-yl)prop-2-en-1-one (33). Following Route C, and
starting from 51 (0.20 g, 1.0 mmol) and pyridine-4-carboxyaldehyde (0.12 g, 1.1 mmol) a solid was
obtained that was filtered under vacuum and crystallized from EtOH to give 33 (0.21 g), 77% yield,
mp 91–93 ◦C. 1H-NMR δ 1.78 (s, 3H, CH3), 1.83 (s, 3H, CH3), 4.62 (d, J = 7.2 Hz, 2H, OCH2), 5.51 (t,
J = 6.8 Hz, 1H, CH), 7.01 (d, J = 8.8 Hz, 2H, H-3 and H-5), 7.48 (d, J = 7.2 Hz, 2H, H-2′ and H-6′), 7.63
(d, J = 15.6 Hz, 1H, β-CH=), 7.71 (d, J = 15.6 Hz, 1H, α-CH=), 8.04 (d, J = 8.4 Hz, 2H, H-2 and H-6), 8.69
(d, J = 7.2 Hz, 2H, H-3′ and H-5′). 13C-NMR δ 18.32, 18.57, 21.41, 64.21, 114.22, 119.65, 123.74, 127.88,
130.51, 138.08, 144.00, 149.16, 164.77, 191.66. ESI-MS (m/z) 294 (M + 1). HRMS ESI + [M + 1]: calcd for
C19H19NO2, 294.1494. Found: 294.1492.
(E)-1-(4-((3-methylbut-2-en-1-yl)oxy)phenyl)-3-(4-nitrophenyl)prop-2-en-1-one (34). Following Route C and
starting from 51 (0.20 g, 1.0 mmol) and of 4-nitrobenzaldheyde (0.17 g; 1.1 mmol) a solid was obtained
that was filtered under vacuum and purified by crystallization from EtOH to give 34 as a brown
powder, (0.26 g) 70% yield, mp 100–102 ◦C. 1H-NMR δ 1.79 (s, 3H, CH3), 1.85 (s, 3H, CH3), 4.62 (d,
J = 7.2 Hz, 2H, OCH2), 5.51 (t, J = 6.8 Hz, 1H, CH), 7.00 (d, J = 8.4 Hz, 2H, H-3 and H-5), 7.63 (d,
J = 15.6 Hz, 1H, β-CH=), 7.79 (d, J = 8.0 Hz, 2H, H-2′ and H-6′), (d, J = 15.6 Hz, 1H, β-CH=), 7.90 (d,
J = 15.6 Hz, 1H, α-CH=), 8.07 (d, J = 9.2 Hz, 2H, H-2 and H-6), 8.29 (d, J = 8.8 Hz, 2H, H-3′ and H-5′).
13C-NMR δ 18.52, 24.11, 64.08, 114.63, 119.08, 121.08, 123.87, 129.45, 129.95, 138.11, 145.36, 163.21, 189.32.
ESI-MS (m/z) 338 (M + 1). HRMS ESI + [M + 1]: calcd for C20H19NO4, 338.1392. Found: 338.1394.
(E)-3-(4-(dimethylamino)phenyl)-1-(4-((3-methylbut-2-en-1-yl)oxy)phenyl)prop-2-en-1-one (35). Following
Route B, and starting from 51 (0.20 g, 1.0 mmol) and 4-(dimethylamino)benzaldehyde (0.16 g, 1.1 mmol),
a red solid was obtained that was filtered under vacuum and crystallized from EtOH to give 35 as a red
powder (0.03 g), 15% yield, 121–123 ◦C. 1H-NMR δ 1.77 (s, 3H, CH3), 1.82 (s, 3H, CH3), 3.05 (s, 6H,
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NCH3), 4.60 (d, J = 6.4 Hz, 2H, OCH2), 5.51 (t, J = 6.8 Hz, 1H, CH), 6.70 (d, J = 8.4 Hz, 2H, H-2′ and
H-6′), 6.98 (d, J = 8.8 Hz, 2H, H-3 and H-5), 7.36 (d, J = 15.6 Hz, 1H, β-CH=), 7.55 (d, J = 9.2 Hz, 2H,
H-3′ and H-5′), 7.79 (d, J = 15.6 Hz, 1H, α-CH=), 8.02 (d, J = 8.8 Hz, 2H, H-2 and H-6). 13C-NMR δ 18.8,
24.36, 41.35, 64.02, 11.33, 111.45, 111.66, 114.25, 119.57, 121.18, 124.61, 129.72, 130.12, 130.97, 131.25,
145.74, 150.01, 163.75, 189.22. ESI-MS (m/z) 336 (M + 1). HRMS ESI + [M + 1]: calcd for C22H25NO2,
336.1963. Found: 336.1964.
(E)-1-(4-(prop-2-yn-1-yloxy)phenyl)-3-(pyridin-3-yl)prop-2-en-1-one (36). Following Route C, and starting
from 52 (0.17 g, 1.0 mmol) and pyridine-3-carboxyaldehyde (0.12 g, 1.1 mmol) a solid was obtained
that was filtered under vacuum and crystallized from EtOH to give 36 (0.17 g), 67% yield, mp 96–98 ◦C.
1H-NMR δ 2.58 (d, J = 2.0 Hz, 1H, CH), 4.82 (d, J = 2.4 Hz, 2H, OCH2), 7.09 (d, J = 9.2 Hz, 2H, H-3 and
H-5), 7.33–7.39 (m, 1H, H-5′), 7.61 (d, J = 16.0 Hz, 1H, β-CH=), 7.80 (d, J = 15.6 Hz, 1H, α-CH=), 7.93
(dd, J = 1.6 and 8.8 Hz, 1H, H-4′), 8.07 (d, J = 8.8 Hz, 2H, H-2 and H-6), 8.64 (dd, J = 1.6 and 8.8 Hz,
1H, H-3′), 8.87 (d, J = 1.6 Hz, 1H, H-2′). 13C-NMR δ 56.98, 76.11, 87.91, 114.22, 114.65, 123.45. 123.87,
129.64, 130.45, 130.76, 132.16, 141.74, 142.03, 149.84, 163.25, 189.99. ESI-MS (m/z) 264 (M + 1). HRMS
ESI + [M + 1]: calcd for C17H13NO2, 264.1024. Found: 264.1022.
(E)-1-(4-(prop-2-yn-1-yloxy)phenyl)-3-(pyridin-4-yl)prop-2-en-1-one (37). Following Route C, and starting
from 52 (0.17 g, 1.0 mmol) and pyridine-4-carboxyaldehyde (0.12 g, 1.1 mmol) a solid was obtained that
was filtered under vacuum and crystallized from EtOH to give 37 (0.20 g), 80% yield, mp 99–101 ◦C.
1H-NMR δ 2.57 (t, J = 2.0 Hz, 1H, CH), 4.79 (d, J = 2.4 Hz, 2H, OCH2), 7.09 (d, J = 9.2 Hz, 2H, H-3 and
H-5), 7.47 (d, J = 8.0 Hz, 2H, H-2′ and H-6′), 7.66 (d, J = 16.4 Hz, 1H, β-CH=), 7.70 (d, J = 16.4 Hz, 1H,
α-CH=), 8.06 (d, J = 8.8 Hz, 2H, H-2 and H-6), 8.69 (d, J = 8.6 Hz, 2H, H-3′ and H-5′). 13C-NMR δ 56.41,
76.11, 78.78, 114.21, 114.68, 123.54, 123.98, 124.54, 127.88, 128.45, 130.02. 130.64, 131.11, 144.56, 149.00,
149.857, 163.24, 189.69. ESI-MS (m/z) 264 (M + 1). HRMS ESI + [M + 1]: calcd for C17H13NO2, 264.1024.
Found: 264.1025.
(E)-3-(4-nitrophenyl)-1-(4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (38). Following Route C, and starting
from 52 (0.17 g, 1.0 mmol) and 4-nitrobenzaldheyde (0.17 g; 1.1 mmol) a solid was obtained that
was filtered under vacuum and crystallized from EtOH to give 38 as a brown powder, (0.16 g) 54%
yield, mp 103–105 ◦C. 1H-NMR δ 2.58 (d, J = 2.0 Hz, 1H, CH), 4.82 (d, J = 2.4 Hz, 2H, OCH2), 7.09 (d,
J = 8.4 Hz, 2H, H-3 and H-5), 7.64 (d, J = 15.6 Hz, 1H, β-CH=), 7.78 (d, J = 8.8 Hz, 2H, H-2′ and H-6′),
7.80 (d, J = 15.6 Hz, 1H, α-CH=), 8.07 (d, 2H, H-3′ and H-5′), 8.87 (s, 1H, H-2), 8.07 (d, J = 9.2 Hz, 2H,
H-2 and H-6), 8.28 (d, J = 8.8 Hz, 2H, H-3′ and H-5′). 13C-NMR (CDCl3) δ 56.21, 76.54, 78.11, 114.77,
121.18, 123.87, 129.11, 130.54, 141.07, 145.98, 147.64, 163.74, 189.60. ESI-MS (m/z) 308 (M + 1). HRMS
ESI + [M + 1]: calcd for C18H13NO4, 308.0923. Found: 308.0922.
(E)-3-(4-(dimethylamino)phenyl)-1-(4-(prop-2-yn-1-yloxy)phenyl)prop-2-en-1-one (39). Following Route B,
and starting from 52 (0.17 g, 1.0 mmol) and 4-(dimethylamino)benzaldehyde (0.16 g, 1.1 mmol), a red
solid was obtained that was filtered under vacuum and crystallized from EtOH to give 39 as a red
powder (0.03 g), 15% yield, 133–135 ◦C. 1H-NMR δ 2.56 (t, J = 2.4 Hz, 1H, CH), 3.05 (d, 6H, NCH3),
4.82 (d, J = 2.8 Hz, 2H, OCH2), 6.70 (d, J = 8.4 Hz, 2H, H-3 and H-5), 7.05 (d, J = 9.2 Hz, 2H, H-3′ and
H-5′), 7.35 (d, J = 15.6 Hz, 1H, β-CH=), 7.55 (d, J = 8.8 Hz, 2H, H-2′ and H-6′), 7.80 (d, J = 15.6 Hz,
1H, α-CH=), 8.04 (d, J = 8.8 Hz, 2H, H-2 and H-6). 13C-NMR δ 41.12,56.21, 76.44, 78.64, 111.10, 114.26,
121.87, 124.68, 129.39, 129.85, 130.22, 130.51, 145.74, 150.63, 164.08, 189.89. ESI-MS (m/z) 306 (M + 1).
HRMS ESI + [M + 1]: calcd for C20H19NO2, 306.1494. Found: 306.1492.
(Z)-6-(prop-2-yn-1-yloxy)-2-(pyridin-3-ylmethylene)benzofuran-3(2H)-one (40). To a solution of 16 (0.17 g,
0.60 mmol) in EtOH (17 mL) at 0 ◦C, NaOH aq solution (0.16 g, 3.33 mmol, dissolved in 1 mL of H2O)
and H2O2 (0.07 mL, 3.33 mmol) were added dropwise. The reaction was stirred at rt for 12 h, then
water was added and the solution was acidified with 2N HCl. The solid formed was separated by
vacuum filtration, dried, and purified by column chromatography (EtOAc/MeOH 9:1) to obtain 40 as
a red solid (0.05 g), 29% yield, mp 121.123 ◦C. 1H-NMR δ 3.42 (t, J = 2.4, 1H, CH), 4.69 (d, J = 2.4 Hz,
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2H, OCH2), 6.26 (d, J = 8.8 Hz, 1H, H-5), 6.28 (s, 1H, H-7), 7.31-7.34 (m, 1H, H-5′), 7.59 (d, J = 8.4 Hz,
1H, H-4), 8.12 (d, J = 8.0 Hz, 1H, H-6′), 8.38 (s, 1H, CH), 8.46 (s, 1H, H-4′), 8.91 (S, 1H, H-2′). 13C-NMR
δ 56.21, 76.11, 78.84, 100.00, 109.54, 112.57, 114.08, 123.22, 125.08, 132.11, 132.55, 132.98, 148.64, 149.74,
152.32, 165.09, 167.46, 18.02. ESI-MS (m/z) 278 (M + 1)). HRMS ESI + [M + 1]: calcd for C17H11NO3,
278.0817. Found: 278.0815.
4.2. Yeast Species and Identification
The yeasts included in the present study were Candida albicans ATCC 10231 (American Type
Culture Collection) and a collection of yeasts recovered from a variety of clinical specimens, i.e., blood,
urine, genital swabs, bronchoalveolar lavage, nail specimens, collected at the Microbiology Unit,
St. Orsola Malpighi University Hospital, Bologna, Italy. The clinical strain isolates were identified
by standard procedures, including colony morphology on chromogenic agar (CHROMagar Candida
medium, Becton Dickinson, Heidelberg, Germany) and confirmed by MALDI Biotyper System using
matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS, Bruker
Daltonik, GmbH, Germany) [28]. The distribution of isolates is reported in Tables 1 and 2.
4.3. In Vitro Susceptibility Testing
The in vitro antifungal activity of the chalcones was evaluated by a microdilution broth method in
accordance with the guidelines provided by the EUCAST Edef 7.3 [22]. Briefly, all strains were cultured
on Sabauraud dextrose, then inocula, prepared at 0.5 McFarland, were diluted 1:20 in RPMI-1640
medium (Gibco®, ThermoFisher Scientific Inc., Waltham, MA, USA), containing glucose 2%, 0.3%
levo-glutamine buffered to pH 7.0 with 0.165 M 3-(N-morpholino)propanesulfonic acid (MOPS) to yield
1-5 × 105 cells/mL. A total of 100 µL of the yeast suspension was inoculated in a 96-well microplate
and incubated with 100 µL of serially 2-fold dilution of the compound in the range 200–6.25 µM.
The following controls were included: yeast suspensions incubated in RPMI-1640 culture medium
(positive growth control), or supplemented with dilutions of DMSO, or fluconazole (Sigma-Aldrich,
St. Louis, MO, USA) as a commercial drug. To check the background turbidity of reagents and the
sterility of the procedure, dilutions of each compound were incubated in RPMI-1640 culture medium,
without yeast inoculum. The inoculated plate was incubated at 37 ◦C for 24 h, and subsequently
the optical density at 630 nm was measured by the Multiskan Ascent microplate reader (Thermo
Fisher Scientific Inc.). The effectiveness of the compounds was expressed as percent inhibition relative
to the positive growth control when the inhibition yielded the 50% at 100 µM. The IC50 value was
determined by interpolation of the dose–response curves generated by plotting the percentages of
growth inhibition, relative to the drug-free control (set to 100% of growth), as a function of the tested
concentrations (on a logarithm scale). Statistical analysis was carried out by the nonlinear regression
method using GraphPad Prism version 5.0 for Windows (GraphPad Software, San Diego, CA, USA).
All assays were performed in triplicate and at least two independent experiments were carried out.
4.4. Effect on Yeast-to-Hyphae Transition
A suspension of C. albicans ATCC 10231 (5 × 105 cells/mL) was prepared in RPMI-1640 culture
medium supplemented with 10% (v/v) FCS (fetal calf serum) and incubated for 2 h at 37 ◦C with
chalcones 1, 3–5, 7, 14, and 28 at IC50 values, in a 48-well flat-bottom polystyrene microplate.
Blastospore and hyphae forms were observed under a light microscope. Cells from at least two
different fields of view were observed and were considered to be germinated if they had a germ tube
at least twice the length of the cell diameter [29].
4.5. Agar-Invasive Hyphal Growth
For the “Spider” agar assay, a medium consisted in nutrient broth 1% (w/v), D-mannitol 1% (w/v),
K2HPO4 0.2% (w/v) and agar 1.35% (w/v) with the addition of chalcones 1, 3–5, 7, 14, and 28 at IC50
values was used [29]. Aliquots (2 µL) of a suspension of C. albicans ATCC 10231 (5× 105 cells/mL) were
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spotted onto medium in triplicate and the morphology of growing colonies was observed following
three days of incubation at 37 ◦C. Spider agar plates without chalcones, containing DMSO, served as
the control. The presence of filaments at the colony edges was determined using a light microscope
under 10×magnification.
4.6. Biofilm Investigation
For biofilm formation, a suspension of C. albicans ATCC 10231 at 5× 105 cells/mL was prepared in
RPMI-1640 culture medium and aliquots of 100 µL were transferred to a 96-well flat-bottom polystyrene
microplate. Cell cultures were treated with 100 µL of chalcones 1, 3–5, 7, 14, and 28 at IC50 values, and
incubated statically for 24 h at 37 ◦C to allow biofilm formation. Following the attachment phase, the
free-floating cells were removed, and biofilms were carefully washed with 200 µL of PBS to remove
planktonic fungi. The biofilm mass was quantified by crystal violet (CV) staining. Briefly, 200 µL of
CV solution (0.1% in water) were added to each well containing a completely air-dried biofilm, and
incubated for 30 min at 37 ◦C. Then wells were washed twice with water to remove the unbound
dye and CV was dissolved with 200 µL of 95% ethanol for 30 min [30]. Finally, 150 µL of the colored
supernatant from each well were transferred to a new microplate and the absorbance was read at
550 nm. The percentage inhibition of biofilm formation for each well containing the compound was
calculated by comparing the biofilm mass formed in the absence of test agent. Six wells for each
treatment regimen were prepared and the experiment was performed twice. Data were reported as
mean OD values ± standard deviation (SD) and one-way analysis of variance (ANOVA), followed
by Dunnett’s multiple comparison test to compare data among the different experimental conditions;
statistically significant differences were determined at p < 0.05.
4.7. Cytotoxicity Tests
African green monkey kidney cells (Vero ATCC CCL-81) were cultured in Eagle’s Minimal
Essential Medium (MEM) (Sigma-Aldrich), supplemented with 10% fetal bovine serum (FBS) (Carlo
Erba Reagents, Milan, Italy), 100 U/mL penicillin, and 100 µg/mL streptomycin at 37 ◦C with 5% CO2.
For experiments, cells were seeded into 96-well plates at 104 cells/well, and incubated at 37 ◦C for
24 h. Following washes with PBS, cell monolayer was incubated with 100 µL of serially 2-fold dilution
of the compound in the range 200–6.25 µM. Both untreated cells and cells incubated with medium
containing solvent dilutions were included in each experiment as controls.
The cell viability was assessed by a WST8-based assay according to the manufacturer’s instructions
(CCK-8, Cell Counting Kit-8, Dojindo Molecular Technologies, Rockville, MD, USA). After 72 h of
incubation, culture medium was removed from each well, the monolayer was washed with PBS, and
100 µL of fresh medium containing 10 µL of CCK-8 solution were added. Following a 2 h at 37 ◦C, the
absorbance was measured at 450/630 nm; data were calculated as the percentage of the cell viability
relative to the untreated controls.
5. Conclusions
In the present study a small library of 40 chalcone-based analogues, differently functionalized
on both A-and B-rings, were evaluated in vitro for their antifungal potential. Interestingly, sixteen
chalcones showed a good inhibitory activity against C. albicans control strain associated with a different
degree of cytotoxicity towards mammalian cells. Among them, a subset of seven derivatives (1, 3–5,
7, 14, and 28) exerted a low systemic toxicity, underlying a favorable SI, i.e., degree of host/fungi
selectivity. These selective inhibitors were then further investigated regarding their spectrum of activity
(collection of Candida spp. and non-Candida spp. isolates obtained from different clinical specimens)
and their capability to affect microbial virulence (yeast-to-hyphae transition, filament invasion, and
biofilm formation). In particular, derivative 28 demonstrated a robust dose-response inhibitory effect
against all the selected Candida spp. and the clinically relevant non-Candida yeasts, thus emerging as
the most relevant antifungal agent of the series.
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On the other hand, compounds 5 and 7, even if associated with a restricted antifungal window,
showed great potential for controlling C. albicans pathogenesis and virulence due to their capability to
interfere with the production of both hyphae and biofilm, perfectly meeting the current paradigm of
anti-infective therapeutics. Indeed, these last compounds combine two modes of action by selectively
interfering with growth and, as an added value, weakening microbial virulence. Indeed, disarming
pathogens rather than killing them is emerging as a novel and effective strategy for infection control.
In summary, this study allowed us to gain insight into the chemical functionalization of the
chalcone involved in a favorable antifungal effect. Compounds 5, 7, and 28 could be regarded as
valuable lead compounds worth modifying with different approaches, aimed at improving and
optimizing the antimicrobial profile.
Supplementary Materials: The following are available online. Table S1. Nonlinear regression parameters of
the dose-response curves of chalcone 28 against C. albicans control strain and all Candida spp. clinical isolates;
Figure S1. Dose-response curves of chalcone 28 obtained with non-Candida yeasts; Table S2. Nonlinear regression
parameters of the dose-response curves of chalcone 28 against non Candida spp. clinical isolates.
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